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1. Introduction 
Bile pigments, such as unconjugated bilirubin (BR) and biliverdin (BV), are 
tetrapyrrolic, dicarboxylic acids belonging to the ‘porphyrin’ class of molecules 
and occur naturally in the body. 
In subcutaneous bruises, tissue macrophages engulf the extravasated red cells 
and convert their haemoglobin to bile pigments, which is the reason for the 
characteristic progressive colour change from dark purple (heme) to blue-green 
(biliverdin) and eventually to yellow (bilirubin) (PIMSTONE et al., 1971). 
The physiological plasma bilirubin concentrations in the human body range from 
5 to 17 µmol/L, predominantly bound to albumin, its carrier protein (STOCKER 
2004).  
The idea that bile pigments might possess medicative properties trace back to 
the traditional Chinese medicine thousands of years ago.  
The pigments were applied in the form of powdered or whole gall stones to 
combat miscellaneous disorders underpinned by inflammation (READ, 1976). 
Unlike in the conventional western medicine: bilirubin was primarily considered 
a toxic by-product associated with the potentially fatal conditions of neonatal 
hyperbilirubinemia, hepatic cirrhosis and viral hepatitis (DOLPHIN, 1979). 
A reversal commenced in the 1900s, when the presence of bilirubin spared 
Vitamin A from oxidation in the intestinal lumen, in vivo (BERNHARD et al., 
1954). This indication was the activator for further research and in succession a 
flurry of publications on possible beneficial effects emerged.  
In the past 20 years the evidence of the physiological relevance of bile pigments 
could be fortified with indication to suggest that bilirubin and biliverdin possess 
powerful antioxidant capacity towards the oxidation of lipids (FREI et al., 1988) 
and proteins (NEUZIL et al., 1993). And, more specifically, bile pigments are 
potent peroxyl radical scavengers and inhibit the mutagenic effects of a number 
of classes of mutagens (polycyclic aromatic hydrocarbons, heterocyclic amines, 
oxidants).  
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Nowadays, consolidated findings concerning the anti-mutagenic and 
antioxidative effects of bile pigments exist and research is still on the rise, since 
these compounds might play a key role in the treatment of cardiovascular 
diseases and cancer, which account for the major cause of death in 
industrialised countries.  
 
Most of the experiments are based on in vitro studies, most frequently using the 
Ames Salmonella microsome assay as a test model. But further research 
investigating the mechanisms of the transactions, as well as cell culture studies 
and finally in vivo research probing are essential to explore the therapeutic 
potential of these naturally occurring compounds (BULMER et al., 2007). 
 
The aim of this thesis was to explore the potential anti-mutagenic and 
antioxidative effects of bilirubin dimethyl ester and biliverdin dimethyl ester in 
the Ames Salmonella assay. The terms “bilirubin dimethyl ester” and ”biliverdin 
dimethyl ester” are used since the natural compounds were esterified to 
enhance the solubility and thereby facilitate the working processes. 
 
The Ames test is always carried out in pairs. My workmate Andrea Steyrer and 
me tested 4 bile pigments – bilirubin dimethyl ester, biliverdin dimethyl ester, 
stercobilin and urobilin - and split these up between the two of us. 
 
This study was part of the FWF project “Bile Pigments - Physiological 
Relevance of Bile Pigments”, in which the physiological relevance of the bile 
pigments, their possible transmission of in vitro to in vivo evidence, the 
compound’s anti-mutagenic and anti-carcinogenic potential and their 
mechanisms of action were investigated.  
Besides the bile pigments bilirubin- and biliverdin dimethyl ester presented in 
this study, stercobilin and urobilin are discussed in the diploma thesis of my 
work-mate Andrea Steyrer. 
Four further compounds, namely bilirubin, biliverdin, bilirubin-ditaurate and 
protoporphyrin were explored by Mag. Christine Mölzer and Hedwig Huber. 
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2. Literature survey 
2.1. The Ames test 
In terms of health risk assessment the Ames test illustrates a relatively quick 
and competitive method to test substances, as for instance new chemicals, 
drugs or biocides for their mutagenic or genotoxic potential. Over the years its 
value as such has been acknowledged by the scientific community, by 
government agencies and corporations. For that reason the test is in use world-
wide as an initial screen. 
In the following, a prevailing review referring to this will be presented. 
2.1.1. Principle of the test procedure 
The Ames Salmonella/microsome mutagenicity assay is a short-term bacterial 
reverse mutation assay specifically designed to detect a wide range of chemical 
substances that can induce genetic damage, leading to gene mutations. 
The test uses a number of Salmonella strains with pre-existing mutations that 
leave the bacteria unable to synthesize the required amino acid histidine. This 
explains why the bacteria are not able to grow and form colonies. 
If a mutagenic substance is added, the gene’s function can be restored and 
allows the cells to synthesize histidine again. These newly mutated cells 
illustrate the wild type of the Salmonella strain which is able to grow and form 
colonies without histidine. On this account the test is often called a “reversion” 
assay. The intensity of the increase of the so called his+ revertants is an 
indicator for the mutagenic potential of the tested substance (MORTELMANS 
and ZEIGER, 2000). In short, the higher the quantity of the revertants, the 
stronger is the mutagen. 
Generally, a compound is classed “pro-mutagenic” if the relative mutagenic 
response increased beyond 200%, relative to the positive control (BULMER, 
2007). 
Some carcinogenic chemicals, such as aromatic amines or polycyclic aromatic 
hydrocarbons, are biologically inactive unless they are metabolized to active 
forms. Since bacteria do not possess a cytochrome-based P450 metabolic 
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activation system, an exogenous mammalian organ activation system can be 
added instead of the buffer solution.  
2.1.1.1 Historical background 
The original Ames test dates back to 1964, when Bruce N. Ames, an American 
biochemist and geneticist developed an assay for the initial screening of a 
number of histidine mutants which led to the selection of mutants that were 
highly sensitive to reversion by a variety of bacterial strains (AMES, 1971). 
This was the pioneering finding for the Ames test and the cornerstone for the 
assay in the way it is performed today.  
The original development took place in 1973, when mutagenic effects on 
bacteria, caused by potent carcinogens, were studied. 
In 1966 the spot test was applied for the first time by Ames and Whitfield, 
previously used with an E.Coli strain. A number of histidine mutant bacteria 
were used to screen chemicals to detect their mutagenic potential by applying a 
small amount of the test chemical directly to the centre of a selective agar 
medium plate which was inoculated with the tester strain. The chemical diffused 
into the agar and built a concentration gradient. If revertant colonies increased 
this was an indication for a mutagenic chemical, whereas total growth inhibition 
was observed if the chemical was toxic. 
It was in 1973 when Ames et al. evolved a more quantitative assay than the 
spot test, namely the plate incorporation assay.  
2.1.2 Bacterial strains 
The concept of carcinogenesis as an expression of mutation in DNA has been 
revived over the past years. Mutations are of different types: base substitutions, 
frame shifts, and larger lesions. For the classification of mutations induced by 
chemical carcinogens, Ames and his co-workers have been developing tester 
systems with the bacterium Salmonella (AMES, 1971). 
The principle of their approach is scoring carcinogen-induced reversion to 
histidine independence of histidine-requiring tester strains. 
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In addition to the genetic histidine dependence, the standard tester strains 
contain other mutations that highly increase their ability to detect mutagenic 
substances (MARON and AMES, 1984). 
These mutations act as hot spots for mutagens that cause DNA damage via 
various mechanisms.  
2.1.2.1 Genotype of the tester strains adopted within the assays 
 
Bacterial 
strain 
His 
mutation 
uvrB-bio LPS 
Defect 
Plasmid Reversion 
by 
TA98 hisD3052 Yes Rfa pKM 101 Frame shift 
mutation 
TA102 hisG428 No Rfa pKM 101, 
pAQ 1 
Oxidative 
damage 
Table 1: Mutation forms of the in the study used Salmonella tested strains 
 
TA98 contains the hisD3052 mutation, TA102 carries the hisG428 mutation. 
Both strains are histidine dependent by virtue of a mutation in the histidine 
operon. Additional mutations/genetic alterations that have made the tester 
strains more sensitive to chemical mutagens are listed below. 
TA98 exhibits a deletion mutation through the uvrB-bio genes. The uvrB 
deletion mutation eliminates the accurate excision repair mechanisms, thereby 
allowing more DNA lesions to be repaired by the error-prone DNA repair 
mechanism. The deletion through the biotin gene results in the bacteria’s 
dependency on biotin (AMES and MC CANN, 1976). 
TA102, not showing the uvrB-bio deletion mutations, is primarily included into 
the set of tester strains for detecting mutagens that require the conventional 
excision repair mechanism (MOERTELMANS and ZEIGER, 2000). 
Rfa-mutation occurs in both strains. This type leads to a defective 
lipopolysaccharide (LPS) layer that coats the bacterial surface, making the 
bacteria more permeable to bulky chemicals (AMES et al., 1976). 
The plasmid pKM101 has been introduced in TA98 and TA102 in order to 
increase the error-prone DNA repair pathway and similarly enhance mutagenic 
changes caused by chemicals.  
TA102 also contains the hisG428 mutation on plasmid pAQ1 to enlarge the 
number of target sites. 
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As a consequence of these mutations and genetic alterations TA98 is typically 
sensitive to frame shift mutations, TA102 is prone to oxidative mutagens 
(MORTELMANS and ZEIGER, 2000; MARON and AMES, 1983). 
2.2 Chemistry of the bile pigments 
 
2.2.1 Chemical basics 
Bilirubin and biliverdin, the oxidised product of unconjugated bilirubin, are 
tetrapyrrolic, dicarboxylic acids belonging to the “porphyrin” class of molecules. 
They possess unique, divergent, three dimensional structures (Fig. 1) 
(BULMER et al., 2007) and show intense colours.  
Although bilirubin is a polar molecule Brodersen et al. explored that the 
solubility of bilirubin in aqueous buffers and under exclusion of light amounted 
to 7 nM at pH=7.4, temperature 37°C, increasing with higher pH, approximately 
in inverse proportion with the squared hydrogen ion concentration. 
Nevertheless, the bile pigment poorly dissolves in most lipid solvents, except for 
asymmetrical chloralkanes. Hydrogen bond-breaking solvents, in particular 
dimethyl sulfoxide, are most effective in solubilizing bilirubin. These internal 
hydrogen bounds in the compound suppress the ionization of the carboxyl 
groups and monopolize all of the polar groups in the bilirubin molecule, limiting 
their interaction with water (BRODERSEN, 1979).  
The very low aqueous solubility of unconjugated bilirubin is less than 0.5% of 
the normal total UCB concentration in the plasma. This explains why the 
majority of UCB is carried in the circulation as water-soluble complexes with 
plasma proteins. 90% of UCB in the adult circulation is bound to albumin, the 
remaining 10% mainly to the apolipoprotein D in high density lipoprotein (HDL) 
(SUZUKI et al., 1988).  
The antioxidant potency of unconjugated bilirubin is enhanced when binding to 
plasma albumin (STOCKER et al., 1987), and possibly to cytosolic proteins 
(BRASS et al., 1989). From this it follows that bound as well as unbound 
unconjugated bilirubin and conjugated bilirubins in plasma and the cytosol are 
available to protect cell membranes from lipid peroxidation. On the other hand, 
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only “free” unconjugated bilirubin, which is not protein bound, can enter cells by 
passive of facilitated diffusion and therefore detects its potential toxic effects 
intracellularly (OSTROW and TIRIBELLI, 2003). 
Binding of bilirubin to albumin sequesters the molecule into a non-toxic form but 
also distributes the pigment throughout the entire circulation and extra vascular 
space (BRODERSEN, 1979). 
Biliverdin, obtainable from bilirubin by abstraction of two hydrogens, is more 
soluble (MINETTI et al., 1997). 
The hydrophobe qualities of bilirubin have both positive and adverse effects. 
As a negative aspect the toxic phenomenon (see chapter 4.2.4) as well as the 
affinity for the pathogenesis of gallstones hast to be mentioned, compared to 
the beneficial function of bilirubin as an effective antioxidant molecule for 
lipophilic substances (see chapter 4.2.2.3) (LÖFFLER and PETRIDES, 2007). 
The fact, that bile pigments are highly photosensitive and additionally tend to 
oxidize at either very low or high pH, requires special attention when handling 
these substances.  
2.2.2 Formation of bile pigments 
In humans unconjugated bilirubin and biliverdin are formed via the catabolism of 
heme, which possesses the prosthetic group of hemoglobin and also other 
heme proteins. Hemoglobin, released from senescent red blood cells, and 
heme containing enzymes are the major source of heme for the synthesis of 
bile pigments (SCHMID and MC DONAGH, 1975). 
The catabolism of heme takes place in the cells of the reticulo-endothelial 
system (e.g. liver, spleen), resulting in the excretion of about 300 mg of bile 
pigments from the body each day (STOCKER; 2004). 
In Fig. 1 the metabolism of bile pigments in the human body is shown.  
Free heme, which is toxic, is degraded by microsomal heme oxygenase (HO-1) 
and then converted forming biliverdin, carbon monoxide and iron by mediating 
stereospecific cleavage (always opening of the α-bridge) of the heme ring. 
Actually this describes the initial rate-limiting step of heme degradation, since 
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one mole of heme is converted to one mole each of Fe2+ and carbon monoxide 
and biliverdin (RYTER et al., 2006). 
In succession, biliverdin is reduced to unconjugated bilirubin, by the cytosolic 
enzyme BVR (SCHMID and MC DONAGH, 1975). BVR offers a stereochemical 
preference for bilirubin IXα. It is most abundant in tissues with high HO activity, 
and is present abundantly, resulting in the absence of biliverdin in human 
plasma or bile (CRAWFORD et al., 1988). 
At first sight, this metabolic event appears to be disadvantageous, since 
bilirubin elimination requires a considerable amount of energy (NADP) but it 
might be interpreted as a hint that bile pigments play a substantial role in 
physiological processes. 
After the formation of bilirubin, this hydrophobic compound is bound to serum 
albumin, for which it has a strong affinity (BRODERSEN, 1979). Bilirubin is 
circulated to the liver where it is actively and passively absorbed into the 
hepatocyte.  
Since bilirubin is toxic and insoluble in aqueous solutions, it must be 
glucuronidated before excretion in the bile (SEDLAK et al., 2008). Hence, 
intercellular glutathione-S-transferase transports bilirubin to the endoplasmic 
reticulum where glucuronic acid conjugates are formed by UDP glucuronosyl 
transferase (UGT1A1) (KAMISAKO, 2000). 
Due to conjugation bilirubin becomes water soluble and is then actively 
transported into the bile caniculi by multidrug resistance protein 2 (MRP2) 
(KEPPLER and KONIG, 2000).  
In the next step the bilirubin conjugates are delivered into the duodenum via the 
bile duct. When bilirubin glucuronides enter the gastrointestinal tract, bacterial 
enzymes including ß-glucuronidase, hydrolyse the bilirubin esters forming an 
unconjugated pigment (SKAR and SAXERHOLT, 1989). 
A part of the unconjugated bilirubin is reabsorbed (GILBERSEN et al., 1962) 
and re-excreted. The remains of the pigments are reduced by the intestinal 
bacterial flora to urobilins and stercobilins, which provide the distinctive 
colouration of faeces (WATSON et al., 1969). 
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Overall, the decomposition of heme is an observable process since the several 
steps of the process are colourfully represented in the time course of bruising 
where the blue-green colour of biliverdin is followed by the yellow colouration of 
bilirubin. Interestingly, in birds and reptiles, which lack the enzyme biliverdin 
reductase, the sequence of bile pigment formation stops at the level of non-toxic 
biliverdin (NEUZIL and STOCKER, 1993). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of the metabolism of heme to biliverdin, bilirubin 
and bilirubin glucuronide (BULMER et al., 2008). 
 
2.2.2 Antioxidative properties of bile pigments 
 
2.2.2.1 General aspects 
Prior to the 1980s bilirubin had been considered a toxic by-product closely 
connected with the possibly fatal conditions of neonatal hyperbilirubinemia, 
hepatic cirrhosis and viral hepatitis. But after the increase of perceptive 
research, bilirubin was identified as an active antioxidant with several 
modulatory properties including anti-viral (BERNHARD and RITZEL, 1953), 
anti-apoptotic (BERNHARD et al., 1954), anti-inflammatory (LAFARGE-
FRAYSSINET, 1983), and anti-compliment (STRAUSS et al., 2006) activities. 
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All these encouraging findings provided new and additional impulse for further 
analysis of the bile pigments. 
Antioxidants are a group of compounds that protect the body’s cells from 
oxidation by quenching reactive oxygen species (ROS). They are seperated into 
the classes simple and enzymatic. Glutathione, vitamin E (tocopherols), vitamin 
C (ascorbate), carotenoids, uric acid and bilirubin are typically small molecules 
belonging to the simple group whereas the enzymatic type of antioxidants is 
larger in size and occurs within and outside biological cells. Enzymatic 
scavengers, such as superoxide dismutase (SOD), catalase (CAT) and 
glutathione peroxidase (GPx) work together in order to transform one free 
radical to another, ultimately reducing them to less harmful molecules like water 
(H2O) and oxygen (O2).  
However, the existing and auspicious results concerning the antioxidative 
capacity of bile pigments, which will be discussed in the following, apply to in 
vitro studies only. Since currently – to the best of our knowledge - there is no 
information available, the efficacy of their supplementation in vivo (HUANG et 
al., 2006) is still unsettled, since they are almost not absorbed into the body via 
anoral supplement. 
 
2.2.2.2 Oxidative stress definition 
Oxidative stress is the consequence of an imbalance between pro- and 
antioxidants in favour of the former. 
Prooxidants (e.g. light, radiation, metallic ions) catalyse redox-reactions or 
homolytic cleavage and, as a result, produce free radicals. These molecules are 
very reactive due to an uneven pair of electrons and can damage biological 
tissues, by competing with these molecules for their electrons. Free radicals in 
vivo include amongst others the superoxide radical cation (O2·-), hydroxyl 
radical (OH·-) and hydrogen peroxide (H2O2·). The latter is an example of an 
oxidant that promotes free radical formation (BERGAMINI et al., 2004).  
Oxidative damage of cell components and alterations of cellular functions are 
the results of continuous exposure to reactive oxygen species (ROS), emerging 
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from exogenous and endogenous sources. In series, excessive generation of 
ROS and other radicals can damage proteins, carbohydrates, polyunsaturated 
fatty acids, and DNA, and may thus lead to oxidative stress and various 
degenerative processes and diseases such as aging, immunodeficiencies, 
neuropathological disorders like Parkinson’s and Alzheimer’s disease, further 
inflammation, diabetes, rheumatoid arthritis and certain cancers (HALLIWELL 
and GUTTERRIDGE, 1999). 
Besides, ROS are also involved in the occurrence of coronary heart disease, 
the major cause of death in industrialised countries. 
By measuring the concentration of specific products, evolved from the damage 
of free radicals, oxidative stress can be quantified.  
For this purpose various different techniques have been developed to monitor 
this process and its consequences. These approaches can also be used to 
identify dietary antioxidants and their mode of action. 
 
2.2.2.3 Bilirubin and its potent antioxidative forms 
 
Bilirubin displays an active antioxidant in the following three forms: 
 
1. Free unconjugated bilirubin 
2. Conjugated bilirubin  
3. Albumin-bound bilirubin. 
 
Ad. 1. Free unconjugated bilirubin: 
In this form bilirubin is particularly effective due to distinctive reactivity with 
superoxyl- and peroxyl anions, as well as the ability to scavenge O2-radicals 
(STOCKER and AMES, 1987). 
 
Ad. 2. Conjugated bilirubin 
Because of its higher water-solubility, conjugated bilirubin circulates free in the 
blood and shows unique efficiency in preventing lipids against oxidation. In 
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comparison, biliverdin displays a 2.5 higher potency in its protective properties 
per molecule (STOCKER et al., 1990). 
 
Ad. 3. Albumin-bound bilirubin 
The prevention of albumin ligands and albumin-bound fatty acids against 
oxidation is the predominant task of albumin-bound bilirubin (TOMARO and 
BATLLE, 2002). 
 
2.2.2.4 Bile pigments in comparison to other antioxidants 
To provide a better overview, results of in vitro results dealing with the 
antioxidative capacity of bile pigments will be given foremost, followed by topical 
in vivo research findings.  
 
In 1953 the antioxidant activity of bile pigments was proposed primarily by 
Bernhard et al. This study depicted a considerable impulse on further research 
since it was demonstrated that the oxidation of Vitamin A could be inhibited 
through co-incubation with unconjugated bilirubin or biliverdin respectively.  
A further fundamental study was presented by Stocker et al. in 1987: 
Bilirubin, bound to human albumin and present at normal concentrations in 
human plasma, protects albumin-bound linoleic acid from peroxyl radical-
induced oxidation in vitro. Initially, albumin-bound bilirubin is oxidized at the 
same rate as peroxyl radicals are formed and, as a result, a stoichiometrical 
amount of biliverdin is produced as the oxidation product. In regard of other 
antioxidants it was shown that on an equimolar basis, albumin-bound bilirubin 
successfully competes with uric acid for peroxyl radicals but in comparison with 
vitamin C it is less efficient in scavenging these radicals. 
This study verified that 1 mol of albumin-bound bilirubin could scavenge 2 mol 
of peroxyl radicals and that small amounts of plasma bilirubin were capable of 
preventing oxidation of albumin-bound fatty acids as well as of the protein itself. 
By this means the role for albumin-bound bilirubin as a physiological antioxidant 
in the plasma and the extra vascular space was confirmed again. 
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In 1994 in vitro studies showed that the oxidation of lipids, in particular low 
density lipoproteins (LDL), could be reduced by unconjugated and conjugated 
bilirubins. Since oxidation of LDL is causally related to the pathogenesis of 
arterial diseases (STOCKER and KEANEY, 2004), these were very auspicious 
results, proposing bilirubin as a cardio-vascular protective compound. 
Concerning lipid peroxidation, bile pigments actually turned out to be the most 
effective free radical generating system amongst all the others. In addition, 
uconjugated bilirubin emerged as an even stronger protector of proteins from 
oxidation than vitamin E in further in vitro studies. As proteins are found 
throughout cells and include transporters and enzymes that are substantial for 
the cell function, this is another noteworthy aspect (NEUZIL et al. 1993). 
 
Another experiment focused particularly on the differences between glutathione, 
a tripeptid which is part of a redox system in the organism, and bilirubin. Both 
compounds represent important endogenous antioxidants and act in a very 
similar way in terms of their metabolism. Both systems contain an oxidized and 
a reduced form, whereas the latter is predominant under healthy conditions. 
However, the hydrophobic bile pigment protects cell membranes from 
lipidoxidation, while the water-soluble glutathione mainly prevents cytoplasmic 
components from radical-mediated damage. In this study, hepatic cells were 
exposed to different concentrations of H2O2 to investigate whether biliverdin 
reductase is able to attenuate oxidative stress related events in the cells. 
When biliverdin reductase was absent, cell death rates increased obviously, for 
glutathione there was just a little effect at one concentration of the oxidant (200 
µM). Bilirubin succeeded in the protection of cells from a 10 000-fold excess of 
H2O2. It is assumed that the biliverdin reductase system is at least as substantial 
as the glutathione system in physiologic cytoprotection (BARANANO et al., 
2002). 
A comparison of the antioxidant properties of bilirubin and biliverdin was 
presented by Asad et al. in 2001. 
For this purpose the inhibition of DNA cleavage, induced by L-DOPA-Cu(II) 
(HUSAIN and HADI, 1995) by both compounds was studied at different 
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concentrations. Bilirubin succeeded and therefore turned out to be the more 
potent antioxidant, since it inhibited the DNA cleavage to a greater extent than 
biliverdin at the same concentration rates. 
 
Generally and according to research results in 1997 it was found that the 
antioxidant role of bilirubin was not that of a preventive antioxidant (antioxidant 
intercepting the initiator of the oxidative process), but appeared to be more 
similar to that of a chain-breaking antioxidant (antioxidant acting on secondary 
oxidants involved in the propagation of the damage) (MINETTI et al., 1997). 
Referring to in vivo effects in humans, actually there do not exist any studies 
involving the oral supplementation of bile pigments. That is why the impact of 
elevated circulating bile pigment concentrations have been determined in 
models in which the increase was induced by exogenous bile pigment 
administration or underexpression of UGT1A1 (Gunn rat), resulting in an 
increased circulating bilirubin concentration. This is for example the case in the 
Gilbert’s syndrome, a condition which appears at birth. 
In 1995 Dennery et al. published the perhaps most widely known in vivo study 
of unconjugated bilirubin protection. It was shown that hyperbilirubinemic Gunn 
rats had reduced levels of plasma oxidative stress, when exposed to chronic 
hyperoxia, compared to control rats with normal serum bilirubin concentrations. 
There was no difference between the groups in regard of serum antioxidant 
concentrations (superoxid dismutase, catalase, glutathione, vitamins A, C, E 
and uric acid) and, therefore they could not account for the decreased 
concentration of oxidative metabolites. Another finding based on the results was 
the apparent negative correlation between serum bilirubin and thiobarbituric 
acid reactive substances, a product of lipid oxidation. In summary, the results 
suggested that a raise of the serum unconjugated bilirubin concentration from 
0.7 to 7 mg/dL in rats can reduce indicators of plasma oxidation, caused by 
hyperoxic exposure. 
 
Later, in 1994, Schwertner et al. were successful with linking the total plasma 
concentration of bilirubin to the prevalence of atherosclerotic disease for the 
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very first time which illustrates a magnificent and encouraging advancement for 
further research. 
Their repeatedly confirmed findings showed that individuals with higher plasma 
bilirubin concentrations were less likely to suffer from several variations of 
cardiovascular diseases including coronary artery plaque formation and 
peripheral arterial disease for instance (PERLSTEIN et al., 2008).  
Concerning biliverdin it was shown that when acting together with unconjugated 
bilirubin in a redox cycle, this compound was a more potent antioxidant pool 
than on its own (BARANANO et al., 2002) and protects the mammalian feto-
placental system from ROS overproduced in placental mitochondria (MYATT, 
2006). 
 
Multiple studies reinforced the antioxidant capacity of mildly elevated serum 
bilirubin levels, as well as activation of heme oxygenase, and pointed at their 
protection from pro-oxidative challenges, also at physiological concentrations.  
Altogether there is abundant evidence supporting the thesis that circulating 
bilirubin concentrations show a negative relationship with the severity of 
atherosclerotic diseases. Now it is imperative to find ways of increasing the 
circulating bile pigment concentration, without causing toxicity resulting from 
accumulated unconjugated bilirubin. 
The limiting factor of toxicity is the plasma’s capacity to bind albumin (600 µM), 
according to this, a considerable scope between 10 µM up to 150 µM is 
supposed to be an adequate range for the protective effects of bile pigments 
and bilirubin in particular (BULMER, 2008). 
2.2.2.5 Mechanism of the antioxidative activity of bile pigments 
The antioxidant properties of bilirubin and biliverdin are predominantly due to 
their ability to scavenge free radical species such as superoxide anion and 
peroxide radicals (FARRERA et al., 1994). 
More precisely it is hypothesised that the antioxidant effects of bilirubin and 
biliverdin are related to their capacity to donate electrons, as bilirubin can 
donate two electrons and biliverdin just one. 
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Stocker et al. demonstrated that bilirubin, during free radical reaction, formed a 
stable free radical with resonance stabilization extending over the entire bilirubin 
molecule (STOCKER et al., 1987a). 
It can be adopted that similar free stable radicals are also able to be formed 
with other porphyrins which possess α-hydrogen atoms adjacent to the 
porphyrin ring (one of the possible products of a free radical reaction with 
protoporhyrin IX is given in Figure 2). 
These radicals can be beneficial for the DNA since they are incapable of 
prolonging free-radical chains (BULMER et al., 2008). 
 
 
Figure 2: Proposed structure of a stable free porphyrin radical forming during interaction of a 
porphyne derivative with active reef radial R· (on the example of protoporphyrin IX). (ODIN AP, 
1997) 
 
In 1987 Stocker et al. dealt intensely with the antioxidant activity of albumin-
bound bilirubin. They pointed out that albumin-bound bilirubin, at concentrations 
found in plasma of healthy adults, was a very efficient peroxyl radical scavenger 
and protects fatty acids transported on albumin from oxidation by these radicals. 
The binding of bilirubin dianion to the primary binding site on albumin is thought 
to involve ion pairing, hydrogen bonding, interactions between amino acid side 
chains and the pigment, thereby fixing the two planar dipyrroles of the bilirubin 
molecule in an out-of-plane position (BRODERSEN, 1979).  
Such asymmetric positioning of the bilirubin molecule on albumin is assumed to 
expose the reactive hydrogen atom at C-10 for initial hydrogen abstraction by 
peroxyl radicals while preventing the two dipyrroles moieties from oxidation. 
Thus, binding to albumin seems to afford both increased specificity and 
reactivity of bilirubin towards peroxyl radicals. Further, the results indicate that 
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each molecule of albumin-bound bilirubin can donate two hydrogens to 
scavenge two molecules of peroxyl-radicals, giving rise to albumin-bound 
biliverdin as the reaction product (STOCKER et al., 1987a). 
Also unbound bilirubin, in solution or when incorporated in liposomes, efficiently 
scavenges peroxyl radicals (Stocker et al., 1987b). 
 
2.2.3 Anti-mutagenic properties of bile pigments 
 
2.2.3.1 General aspects 
Because of an increased rate of mutations and the related possible risks of 
cancer in humans, discovery and exploration of chemical compounds with anti-
mutagenic and anticarcinogenic potency are of great importance at the present 
time (ODIN, 1997). 
Adjacent to the conclusion that bile pigments possess considerable 
antioxidative activity, the evidence for their additional anti-mutagenic potential 
has also been mounting during the last 20 years. These precisely not useless 
by-products of heme catabolism inhibit the mutagenic effects of numerous 
classes of mutagens (e.g. polycyclic aromatic hydrocarbons, heterocyclic 
amines, oxidants) but despite the encouraging in vitro anti-mutagenic effects of 
bile pigments, relatively little research probing their protective capacity in 
bacterial and cultured cell assays of mutation has been conducted to possibly 
link the available in vitro with the in vivo observations. 
Spontaneous mutation is thought to occur as a result of imperfect DNA 
recombination and repair processes as well as from the production of 
intracellular free radicals that alter genomic structure. 
As bile pigments show anti-mutagenic activity and are present at high 
concentrations in the bile and intestines of humans, their presence could 
possibly influence the genotoxicity of food derived mutagens in the human diet. 
Additional study of the bile and intestinal bile pigments could further elucidate 
the physiological and anti-mutagenic importance of these compounds in the 
gastrointestinal tract and the human body (BULMER et al., 2007). 
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Most of the anti-mutagenic investigations have utilized the Salmonella 
mutagenicity assay as a model. Table 3 gives a review of several studies that 
have been published concerning this matter, mainly with reference to this thesis 
(tested compounds, strains and mutagens). 
2.2.3.2 Anti-mutagenic effects of bile pigments in the Ames test  
Numerous experiments exploring the antigenotoxicity (equivalent with the term 
mutagenicity) of the porphyrins have enhanced bacterial cells.  
In table 3 a selection of published data is summarised. 
In most of the conducted tests besides bilirubin and biliverdin, tetrapyrolles 
including hemin, chlorophyllin or protoporphyrins have been tested,  
 
Arimoto et al. explored the antigenotoxic affectivity of the porphyrins hemin, 
chlorophyllin, bilirubin and biliverdin against the mutagenicity of 6 amino acid 
pyrolysis products from soy bean, namely Trp-P-1, 3-amino-1-methyl-5H-
pyridol[4,3-b]indole (Trp-P-2), Glu-P-1, 2-amino-dipyrido[1,2-α:3’2’d]imidazole 
(Glu-P-2), 2-amino-9H-pyrido[2,3-b]indole (amino-α-carboline), and 2-amino-3-
methyl-9H pyrido[2,3-b]indole (aminomethyl-α-carboline). All of the experiments 
were conducted with metabolic activation. Hemin and chlorophyllin depicted 
strong anti-mutagenic activity in all classes. Protoporhyrin IX (hemin without 
central iron molecule) was active in three tests only (against Trp-P-1, Trp-P-2, 
and aminomethyl-α-carboline), biliverdin was less active while bilirubin had no 
effect. The addition of hemin to the preincubation mixture in the Ames test 
resulted in strong inhibitions for benzo[α]pyrene and Aflatoxin B1. Generally, 
50% inhibition could be reached by an amount of hemin 1-2 equivalent to the 
mutagen whereas the anti-mutagenic capacity of bilirubin, biliverdin and 
chlorophyllin in inhibiting benzo[α]pyrene-induced mutagenicity turned out to be 
significantly lower. These studies point out that the tetrapyrrole macrocycle is 
crucial for complexing. Therefore hemin, chlorophyllin, and protoporphyrin IX 
were significantly more effective than open tetrapyrroles such as biliverdin and 
bilirubin (ARIMOTO et al., 1980b). 
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A further study by Arimoto et al. concentrated on the possible anti-mutagenic 
effects of hemin, bilirubin and biliverdin against benzo[α]pyrene, a polycyclic 
aromatic hydrocarbon derived from the combustion of fossils fuels. The findings 
indicated that bile pigments were potent anti-mutagens in the TA98 strain with 
the 50% inhibition dose (ID50) for bilirubin and biliverdin approximating 50 and 
500 nmol/plate, respectively. Bilirubin was considered to be more effective than 
biliverdin in inhibiting mutations in the TA98 strain caused by benzo[α]pyrene in 
this study (ARIMOTO et al., 1980a), but in more recently published data 
biliverdin exceeds the effectiveness of bilirubin and bilirubin ditaurate against 
benzo[α]pyrene. In the latter study the ID50 for bilirubin, biliverdin and a water 
soluble bilirubin conjugate, bilirubin ditaurate equalled 658, 284 and 576 
nmol/plate, respectively (BULMER et al., 2007).  
Another investigation was made under similar conditions but with strain TA100. 
The effects of benzo[α]pyrene and its purified metabolites B[α]P-7,8-diol, B[α]P-
4,5-epoxide and B[α]P-7,8-diol-9,10-epoxide on bilirubin and biliverdin were 
tested in the presence of metabolic activation, which depicts the main difference 
to the study mentioned before. In this experiment bilirubin and biliverdin 
inhibited benzo[α]pyrene induced mutation. The ID50 for the two compounds 
constituted approximately 500 and 1000 µmol/plate, respectively, when 
incubated with 10 nmol/plate of the mutagen. Also a weak anti-mutagenic 
activity against the metabolites of benzo[α]pyrene, B[α]P-4,5-epoxide and 
B[α]P-7,8-diol-9,10-epoxide, was verified. In order to elucidate the mechanism 
of antimutagenicity, the porphyrins were incubated with benzo[α]pyrene and S9 
while the synthesis of 3-hydroxyB[α]P was measured. Hemin and Fe-chlorin 
succeeded in inhibiting the above-mentioned synthesis, whereas bilirubin and 
biliverdin prevented the process to a lesser extent but were able to interfere with 
the activation of the precursor of benzo[α]pyrene. Another experiment followed 
in order to test whether the bile pigments accelerated the degradation of 
benzo[α]pyrene metabolites, but this assumption could not be verified 
(ARIMOTO et al., 1995). 
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However, by now the mechanisms of bile pigments on the binding and 
metabolism of benzo[α]pyrene are not clearly understood and thus further 
research is needed. 
To pursue with the relevance of structural circumstances, Bulmer et al. intended 
to ascertain whether bile pigments could selectively inhibit the genotoxic effects 
of mutagens with specific three-dimensional conformations. For this purpose, 
previously untested combinations of bile pigments and mutagens such as 2,4,7 
trinitrofluorenone (TNFone) (without metabolic activation) and 2-aminofluorene 
(2-AF) (with metabolic activation), which possess planar and non-planar 
stereochemistries (Figure 4), were applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Three-dimensional, energy minimised (MM2) structures of unconjugated BR (A), 
unconjugated BV (B), 2,4,7 trinitrofluorenone (C) and 2-aminofluorene (D) (BULMER et al., 
2007) 
 
Another intention of the experiments was to explore whether bile pigments 
would show anti-mutagenic effects when incubated with the oxidant tertiary-
butyl hydroperoxide (t-BuOOH), suggesting a multi-modal mechanism of action. 
The tests were conducted in three strains of Salmonella typhimurium (TA98, 
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TA100, TA102) to establish whether the compounds were able to modulate 
spontaneous or induced genotoxicity.  
Regarding the anti-mutagenic effects, the observation that bile pigments had 
inhibited benzo[α]pyrene induced mutation previously could be supported, 
presenting biliverdin as more potent than the other bile pigments tested. The 
ID50 of bilirubin ditaurate amounted to 0.58 mol, the one of BR to 0.66 mol, 
suggesting the conjugation of bilirubin had no influence on its anti-mutagenic 
potential. For TNFone and 2-AF induced mutation, a common trend in all strains 
could be observed when the anti-mutagenic effects of the bile pigments were 
tested. The order of effectiveness in respect of the ID50 turned out to be as 
follows: 
BR≥BRT>BV for TNFone and BV≥BRT≥BR for 2-AF. As the results were similar 
in all strains when no metabolic activation was applied, this leads to the 
suggestion that bile pigments affected the ability of TNFone to disrupt DNA 
structure. Regarding 2-AF it should be noted that only in the presence of the 
microsomal S9 fraction, its metabolism to the mutagenic compound 2-
acetylaminofluorene is possible. This might explain the anti-mutagenic effects of 
bile pigments against 2-AF induced mutation, since the cytosolic enzymes are 
not active in the S9 mix, in addition to binding/inactivation of the mutagens. 
The affinity of porphyrins for planar aromatic compounds is known and suggests 
that bile pigments could protect from genotoxicity by interacting with these 
mutagens, possibly via π-stacking, hydrogen bonding or hydrophobic 
interactions (ARIMOTO et al., 1995). 
 
As already mentioned, the multi-modal mechanism of action of bile pigments 
was also tested, either with or without metabolic activation. For this purpose 
TA102 was incorporated as a second strain. One characteristic of this strain is 
its susceptibility to oxidative stress induced mutation. The appropriate mutagen 
for this purpose was t-BuOOH, which causes DNA damage in vitro (EPE et al., 
1990) via the generation of reactive oxygen species (ROS), including alkoxyl 
radicals (MINOTTI et al., 1986). The findings showed that bilirubin as well as 
biliverdin attenuated t-BuOOH induced mutation. Metabolic activation did not 
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influence the results. With an ID50 of 0.556 µmol, amounting to approximately 
half of that of biliverdin, bilirubin exhibited its effectiveness to a much greater 
extent. According to observations (STOCKER, 2004), this could be explained by 
bilirubin’s capacity to neutralise two radicals via initial hydrogen atom donation, 
resulting in a bilirubin radical, which binds to another radical forming a non-
radical complex (STOCKER et al., 1987b). In contrary, biliverdin accepts only 
one electron with the formation of a resonance stabilised biliverdin radical 
complex (STOCKER et al., 1987b). 
In summary, the results charge both, bilirubin and biliverdin, a more efficient 
protection against oxidative stress induced mutation than many other 
antioxidants. For instance caffeic acid and α-tocopherol had, compared to the 
bile pigments, only little (EDENHARDER and GRUNHAGE, 2003), if any 
(GREY and ADLERCREUTZ, 2003), anti-mutagenic potential in the presence of 
t-BuOOH. 
The data presented cannot be translated to the in vivo condition but 
nevertheless they do fortify other anti-mutagenic and anti-carcinogenic evidence 
including bilirubin’s apoptotic effects in colon cancer cell lines (KESHAVAN et 
al., 2004), and emphasize the negative correlation between circulating bilirubin 
concentrations and cancer mortality (TEMME et al., 2001). 
Remarkably, the anti-mutagenic effects of bilirubin ranged between ~3 to 250 
µM, encompassing the plasma bilirubin concentrations found in healthy persons 
(~ 12 µM) (HOPKINS et al., 1996), in those with Gilbert’s Syndrome (~ 40 µM) 
(NAIMAN et al., 1996) and in Crigler-Najjar syndrome (~ 80-280 µM) 
(YOUNOSSI and FOROOZAN, 1995). 
To respond to the possible anti-mutagenic effects of porphyrin derivatives on 
cigarette smoke condensate and Swedish moist oral snuff, a study of Romert et 
al. will be presented in the following. The compounds hemin, biliverdin 
dichloride and chlorophyllin were tested in strains TA98 and TA100. 
Compared to hemin and chlorophyllin, biliverdin was not as effective, especially 
in strain TA98 biliverdin did not decrease the number of mutant colonies beyond 
the 50% line. 
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To concretise the results, in TA100 the ID50 values for biliverdin amounted to 
approximately 0.4 µM, whereas for chlorophyllin it constituted about 0.1 µM 
(ROMERT et al., 1994).  
However, in lower concentrations the results of the anti-mutagenic potential of 
chlorophyllin and hemin respectively were inconclusive. 
The main difference in effectiveness between biliverdin and bilirubin compared 
to hemin and chlorophyllin become apparent in the compound’s structures. 
Both, hemin and chlorophyllin, possess a chelated metal ion which seems to be 
crucial for the anti-mutagenic activity. According to this fact the automatic 
drawing of conclusions between the anti-mutagenic potential of the discussed 
compounds are limited. 
Tang and Edenharder investigated the same compounds in regard of their 
potential to inhibit the induced mutagenicity of 2-nitrofluorene, 3-
nitrofluoranthren and 1-nitropyrene in strain TA98. Strong anti-mutagenic 
activity was observed for hemin and bilirubin, while biliverdin and chlorophyllin 
were also active but to a lesser extent (TANG and EDENHARDER, 1997).  
 
Another series of experiments focussed on the ability of bilirubin, and 89 other 
potential anti-mutagens, to inhibit cigarette smoke and 4-nitroquinoline-1-oxide 
(4NQO) induced mutation in strain TA98 and TA100. Bilirubin showed 
considerable activity against both mutagens in strains TA98 and TA100.  
Biliverdin was unable to affect the mutagenic effects of 4NQO (CAMOIRANO et 
al., 1994) in the latter strain, in strain TA98 no tests were conducted. 
 
In summary all the studies mentioned support the theory that bile pigments 
possess anti-mutagenic skills. Nevertheless, further research is needed for a 
better understanding of the apparent in vivo importance and for exploring the 
therapeutic potential of these naturally occurring compounds. 
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2.2.3.3 Mechanism of the bile pigment’s anti-mutagenic effects  
Bilirubin and biliverdin are a part of the porphyrin family of molecules. Porphyrin 
derivatives, such as chlorophylls and hemoglobins, which include 
metalloporphyrins as the active part are widespread in nature and display cyclic 
aromatic polyamines containing a system of conjugated double bonds along the 
whole contour of the porphyrin macrocycle. Thereby a planar molecule of strong 
aromatic nature is formed (BEREZIN and ENIKOLOPJAN, 1985). 
As the chemical structure determines the unique biochemical and genetic 
properties of the porphyrins to a considerable extent, it will be discussed in the 
following. 
Bilirubin and biliverdin are part of the physiological metabolism and catabolism 
of heme which is formed by adding iron to protoporphyrin. When the iron 
molecule is removed and the protoporphyrin ring is cleaved (-CO), biliverdin is 
formed and reduced to bilirubin in the next step. 
When studying the anti-mutagenic potential of these compounds it becomes 
obvious that the specific addition and removal of functional groups could be of 
particular importance. Related to this, one would expect significant differences 
in anti-mutagenic effects between protoporphyrin and heme due to the 
incorporation of Fe III into the centre of the fused protoporphyrin ring and the 
resulting structural distinctions. In effect, the addition of a chelated iron 
molecule could confer the ability to bind additional molecules, possibly 
detoxifying them. Another indicator for this hypothesis is driven by the fact that 
adding metals, including copper, to chlorines increases the detoxification of 
polycyclic aromatic hydrocarbons. In addition, when the ring is opened and fully 
conjugated in consequence of the removal of CO, the structure of biliverdin is 
less potent than protoporphyrin, suggesting the facility that the planarity of 
porphyrins may affect their anti-mutagenic potential (ARIMOTO et al., 1995).  
In a study by Arimoto et al. bilirubin turned out not to be anti-mutagenic when 
being folded into a three dimensional ridge-tile conformation after the 
hydrogenation of biliverdin at the C10 methine bridge (see Figure 4). 
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Figure 4: Two- and three-dimensional structures of bilirubin (1) and biliverdin (2) (Bulmer et al., 
2008) 
 
Due to the hydrogen bonded and folded conformation of bilirubin, it is possible 
that a planar tetrapyrrolic structure (e.g. protoporphyrin, biliverdin) is also 
essential for anti-mutagenic binding of the amino acid pyrolysis products. 
Studying the structurally related porphyrins including protoporphyrin, heme, 
biliverdin, bilirubin and other hydrogenated and oxidised products, could support 
in establishing the structure-activity relationships of these compounds. In a 
study by Bulmer et al. (2008) the anti-mutagenic effects of the bile pigments 
were dependent on the mutagen that was tested and dependent of the strain 
used in the test, suggesting some interaction between the pigments and the 
mutagens  
 
Currently, there is not a single known mechanism to fully explain the anti-
mutagenic activity of porphyrins, only some common agenda concerning their 
antigenotoxic effects. Thorough discussion in order to clarify the possible role in 
mutagen detoxification and DNA repair for each compound of the porphyrin 
family is necessary (ODIN, 1997). 
2. Literature survey 26 
2.2.3.4 Mutagens used in the project 
 
• Aflatoxin B1 (AFB1) 
Aflatoxins are a family of structure related mycotoxins and produced as 
secondary metabolites by the spoilage of fungi Aspergillus, particularly A. flavus 
and A. parasiticus (SWEENEY and DOBSON, 1998). Amongst others, AFB1 is 
one of the most important members, depicting the most frequent metabolite in 
contaminated food samples with a clarification in the group I as carcinogens to 
humans (SIMON et al., 1998). Aflatoxins are commonly found in peanuts 
(STROKA et al., 2000), maize (SCUDAMORE and PATEL, 2000) and other 
nuts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
 Picture 1: Aflatoxin B1  
       
                          Figure 5: AFB1 
 
• 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP) 
PhIP belongs to the group of heterocyclic aromatic amines, a class of 
hazardous chemicals that are receiving heightened attention as a risk factor for 
human cancer. These heterocyclic aromatic amines arise during the cooking of 
meats, fish, and poultry, and several of these substances also occur in tobacco 
smoke condensate and diesel exhaust. DNA adducts of heterocyclic aromatic 
amines have been detected in human tissues, demonstrating that they induce 
genetic damage even though the concentrations of these compounds in cooked 
meats are generally in the low parts-per-billion (ppb) range (TURESKY, 2007). 
  
 
      
       
    
Picture 2: PhIP                    Figure 6: PhIP 
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• 2,4,7 trinitrofluorenone (TNFone) 
 
TNFone is a non-planar polycyclic nitro-amine, not commonly found in the 
environment, but previously found in photocopy toner (KARI, 1992). 
 
 
 
 
        Picture 3: TNFone 
 
         Figure 7: TNFone 
 
 
 
 
 
• Tertiary butyl hydroperoxide (t-BuOOH) 
This mutagen is an organic hydroperoxide and oxidant.  
Although rarely handled, oxidants have been used in several studies of anti-
mutagenic investigation to figure out whether oxidative stress induced mutation 
and carcinogenicity can be inhibited by bile pigments (BULMER et al., 2007). 
 
 
 
 
            
            
   
 
Picture 4: t-BuOOH                                        Figure 8: t-BuOOH 
 
2. Literature survey 28 
 
 
3 Bulmer et al ., 2007
TA98, 
TA100, 
TA102
BR, BV, BRT (0-2 mol) TNFone, 2-AF, NaN3, t -BuOOH
B[α]P (TA98, + S9), 
TNFone (TA98, 
TA100, TA102, - S9), 
2-AF (TA98, TA100, 
TA102, + S9), NaN3 
(TA100, - S9), t -
BuOOH (TA102, +/- 
S9)
The anti-mutagenic effects of the bile 
pigments depended on the tested mutagen. 
Endogenous bile pigments inhibit oxidative 
stress induced mutation.                                   
TNFone: BR=BRT>BV                                               
2-AF: BV>BRT>BR                                                    
B[α]P: BV>BRT>BR                                                      
t -BuOOH: BR>BV>BRT                                                
ID50 BR, BV, BRT: 0.557;1;2.756 mol         
(t -BuOOH – S9)
4 Arimoto et al ., 1995 TA100
BR, BV, Cu-chlorin, Fe-chlorin, 
hemin, protoporphyrin, 
chlorophyllin
B[α]P, B[α]P(7,8)D, 
B[α]P(4,5)E, 
B[α]P(7,8)D(9,10)E
+/- S9
Order of efficiency without metabolic 
activation (-S9) was:                                        
Hemin=protoporphyrin>                                     
hematoporphyrin=Cu-chlorin>                                               
Fe-chlorin=chlorophyllin =BR>BV                                    
Order for BP(4,5)E and BP (7,8)D(9,10)E:                                    
Hemin>chlorophyllin>proto-
porphyrin>hematoporphyrin>BR=BV                                    
Both, hemin and Cu-chlorin accelerated 
degradation of                                    
B[α]P(7,8)D(9,10)E,                                                   
BR and BV suppress B[α]P metabolism by 
S9, but do not accelerate B[α]P metabolite 
degradation
According to the ID50 for B[α]P the order of 
effectiveness was:                                                   
Hemin>BR>chlorophyllin>BV                                           
ID50 BR, BV: 0.05 vs. 0.5 mol, hemin: 0.01 
mol
B[α]P + S9
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Pyrrole pigments were effective against all 
six mutagens in the following order: 
hemin>chlorophyllin>BV                               
Protoporphyrin inhibited only the 
mutagenicity of Trp-P-1, Trp-P-2 and 
MeAαC                                                                             
BR did not show any anti-mutagenic effect
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2 Arimoto et al . 1980a TA98
1 Arimoto et al . 1980b TA98
BV (0-2 mol), hemin, 
protoporphyrin, chlorophyllin
Amino acid pyrolysis 
products: Trp-P-1, Trp-
P-2, Glu-P-1, Glu-P-2, 
AαC, MeAαC
+ S9
BR (0-1.6 mol), BV (0-0.75 
mol), hemin, chlorophyllin
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5 Romert et al., 1994
TA98, 
TA100
BV (0-4 mol), hemin, 
chlorophyllin CSC, SNUS +/- S9
Explicit anti-mutagenic results only for 
hemin and chlorophyllin                                           
BV was less effective, especially in TA98                        
Order of effectiveness in TA98:                         
Hemin=chlorophyllin>BV                                        
TA100:                                                        
Chlorophyllin>BV?hemin                                              
ID50 BV TA98: n/a, TA100:3.8 mol
7
TANG and 
EDENHARDER,
1996
TA98 BV (1 mol), BR (7 mol), hemin, 
chlorophyllin
2-nitrofluorene, 3-
nitrofluoranthren, 1-
nitropyrene
None
All porphyrins and related compounds 
exerted an anti-mutagenic effect against the 
three mutagens.                                                      
Order of effectiveness:                                 
BR?hemin>BV?chlorophyllin
Cigarette smoke, 4-
nitroquinoline-1-oxide
BR was the only compound capable of 
inhibiting mutagenesis of both mutagens.
TA98, 
TA100
BR, BV (0-10 mol), hemin, 
chlorophylin (90 compounds in 
total)
Cigarette smoke                 
(+ S9, TA98),                                  
4NQO (-S9, TA100)
6 CAMOIRANO et 
al ., 1994
 
    Table 2: Bile pigments and other pyrrolic compounds in the Ames test 
 
 
 
 
Abbreviations: 
Compounds: BR=bilirubin, BV=biliverdin; 
Mutagens:Trp-P-1=3-amino-1,4dimethyl-5H-pyrido[4,3-b]indole;Trp-P-2=3-amino-1-methyl-5H-
pyrido[4,3-b]indole;Glu-P-1=2-amino-6-methyl-dipyrido[1,2-a:3’,2’-d]imidazole;Glu-P-2=2-
aminodipyrido-[1,2-a:3’,2’-d]imidazole;AαC=2-amino-9H-pyrido[2,3-b]indole;MeAαC=2-amino-
3methyl-9H-pyrido[2,3-b]indole;b(α)P=benzo(α)pyrene;TNFone=2,4,7 trinitrofluorenone;2-AF=2-
aminofluorene;NaN3=sodium azide; t-BuOOH=tertiary butyl hydroperoxide;S9=microsomal liver 
homogenate; B[α]P(7,8)D=benzo(α)pyrene-trans-7,8-dihydrodiol; B[α]P(4,5)E=4,5-dihydro-
benzo[α]pyrene-4,5-epoxide; B[α]P(7,8)D(9,10)E=benzo[α]pyrene-trans-7,8-dihydrodiol-9,10-
epoxide(anti); CSC=cigarette smoke condensate; CS=cigarette smoke;SNUS=extract and 
subfractions of Swedish moist oral snuff;4NQO= 4-nitroquinoline-1-oxide
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2.2.4 The toxicity of bile pigments 
As bilirubin is a weakly-polar, poorly-soluble compound, the lion’s share of 
plasma bilirubin in circulation (5-15 µM) is tightly bound to serum albumin 
(BLOOMER et al., 1971), with less than 0.01% of total bilirubin circulating in an 
unbound form (free bilirubin). This fraction allows the diffusion of UCB into 
tissues, and therefore free bilirubin is responsible for both its beneficial and 
toxic effects on cells. While normal to modestly elevated plasma bilirubin levels 
are cytoprotective, higher plasma and tissue bilirubin levels often show cytotoxic 
effects (VÍTEK and OSTROW, 2009). 
Plasma concentrations which reach values greater than 300 µM are associated 
with the risk of developing neurological dysfunctions (MEUWISSEN and 
HEIRWEGH, 1982) impairment of cellular functions in the brain tissue 
(SCHENKER et al., 1986) and neonatal hyperbilirubinemia since the liver’s 
capacity to excrete bilirubin is exceeded. Disordered hepatic function, including 
mild (Gilbert’s syndrome) and severe (Crigler-Najjar syndrome) deficiencies in 
UGT1A1 also result in increased circulating bilirubin concentrations. However, 
bilirubin toxicity is rarely observed in these persons and with the use of 
phototherapy or, if the worst comes to the worst, a liver transplantation, 
elevated bilirubin levels can be cured (STRAUSS et al., 2006). 
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3. Materials and methods 
3.1 Methods 
3.1.1 Experimental design 
Based on other studies, six doses of BRDME and BVDME were used in the 
Ames test (0.01, 0.05, 0.1, 0.5, 1 and 2 µmol/plate). The assay was performed 
according to Mortelmans and Zeiger with 25 min of preincubation. The assay 
was performed in a dimly lit laboratory and the bile pigment solutions were 
protected from light using foil covered containers and amber cups. The pipetting 
sheme was as follows: 500 µL of PBS or S9 mix followed by 100 µL of overnight 
bacterial culture, 200 µL of bile pigment solution (DMSO) and finally 100 µL of 
mutagen solution (DMSO). The test tubes were incubated for 25 min at 37°C on 
a rotary shaker. 
Afterwards 2 mL of molten agar was added to every tube, which was vortexed 
and poured onto minimum glucose agar plates. After 20 to 30 minutes drying 
time the plates were put in the incubator for 48 h at 37°C and the His+ 
revertants were counted manually after that. Three plates were counted for 
every concentration of each condition and each test, except one (AFB1 120 
g/ml, TA102) was repeated on another day. In every test, three ‘positive 
control’ (mutagen only) and six ‘negative control’ (no mutagen or bile pigment) 
plates were included. The modulatory effects of bile pigments were investigated 
in two testing paradigms. Firstly, a series of experiments investigating the pro- 
and anti-mutagenic effects of the test compounds, in the presence of known 
mutagens, were conducted. In a second procedure the mutagenic effects of the 
bile pigments only was tested. 
3.1.2 Chemicals 
Bilirubin dimethyl ester [CAS # 19792-68-8] and biliverdin dimethyl ester [CAS # 
10035-62-8] were acquired from Frontier Scientific (Logan, UT, USA). MP 
Biomedicals (Illkirch, France) delivered the S9 liver homogenate. 
All mutagens and other reagents were of analytical grade or better and stored at 
– 80°C if necessary. 
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  Picture 5: Biliverdin dimethyl ester 
3.1.3 Bacterial strains 
The S. typhimurium strains TA98 and TA102 were obtained from Dr. Bruce N. 
Ames (University of California, Berkley, USA). Stock bacteria were stored at  
-80°C as frozen permanents prepared from bacterial overnight culture dissolved 
in DMSO (MORTELMANS and ZEIGER, 2000). For the experiments of this 
thesis the master plates from the foregoing working-team could be adopted.  
3.1.4 Preparation of the samples 
The bile pigment samples, tested for their anti-mutagenic and antioxidative 
potential respectively, were investigated at the University of Vienna, Department 
of Nutritional Sciences.  
The compounds were mainly delivered in vials, containing 150 mg of the 
intensely coloured, powdered substances. 
The preparation of the bile pigments followed the principle of a dilution series. 
Beforehand, 9 mg of the light sensitive samples were weighed in into brown 
coloured microtubes. For both compounds 6 different concentrations (2 µmol, 1 
µmol, 0.5 µmol, 0.1 µmol, 0.05 µmol, 0.01 µmol), made of a stock solution, were 
tested. 
The stock solutions, prepared individually for BRDME and BVDME, consisted of 
the 9 mg weighted sample and 618 µL DMSO. 
The solutions were then put into the ultrasonic bath for 3 min, to enhance the 
better solubility of the samples. 
Afterwards the dilutions were conducted in the following order: 
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concentrations dilution 
2 µmol 320 µl of stock solution + 480µL 
DMSO 
1 µmol 160 µL of stock solution + 640 µL 
DMSO 
0.5 µmol 80 µL of stock solution + 720 µL 
DMSO 
0.1 µmol 100 µL (1 µmol) + 900 µL DMSO 
0.05 µmol 100 µL (0.5 µmol) + 900 µL DMSO 
0.01 µmol 100 µL (0.1 µmol) + 900 µL DMSO 
Table 3: Preparation of the samples 
 
 
 
 
 
  
 
                 Picture 6: Dilution of the samples 
 
 
Picture 7: Top left: BR at highest (2 mol/plate), top left: BR lowest 
concentration (0.01 mol/plate); below left: BV at highest 
concentration (2 mol/plat), below right: BV at lowest concentration 
(0.01 mol/plate) 
 
3.1.5 Evaluation of mutagenicity 
The classification of the tested compounds as “mutagenic”, “pro-mutagenic” and 
“anti-mutagenic” was declared according to the guidelines published by 
Mortelmans and Zeiger (2000). 
3.1.6 Mutagenic testing 
The substances were identified as a “mutagen” if two criteria were applicable: 
Firstly a dose dependent increase in the number of revertants and secondly the 
number of revertants was equal to or exceeded 2fold negative control counts. 
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3.1.7 Pro/anti-mutagenic testing 
The relative pro- and anti-mutagenic responses were calculated for each 
compound, in each condition, relative to the positive control, using the following 
equation. 
 
No. revertants formed [test compound] – No. revertants formed [negative control*100 
No. revertants formed [positive control] – No. revertants formed [negative control] 
 
A compound was classified “anti-mutagenic” if the relative mutagenic response 
fell below 50%. A compound was classified “pro-mutagenic” if the relative 
mutagenic response increased beyond 200% (MORTELMANS and ZEIGER, 
2000). 
Additionally dose dependency was necessary according to Mortelmans and 
Zeiger. To facilitate the comparison between the different doses the results 
were specified per µmol/plate. 
In order to visualise trends, mathematical algorithms were fitted to the data. The 
algorithm with the best fit for each compound in each condition was determined 
by observing the R² co-efficient and these algorithms were superimposed onto 
the results figures (MORTELMANS and ZEIGER, 2000). The results are 
presented in chapter 6, the 50% inhibition doses (ID50) of the bile pigments and 
the inhibition percentage at 0.5 µmol/plate (I0.5) and at the highest dose tested 
(Imax) are illustrated on page 37. 
3.2 Main features of the Ames test 
 
3.2.1 Principle of the assay: 
The Salmonella typhimurium/microsome assay (Salmonella test; Ames test) is a 
widely accepted short-term bacterial assay for identifying substances that can 
produce genetic damage that leads to gene mutations. The test uses a number 
of Salmonella strains with pre-existing mutations that leave the bacteria unable 
to synthesize the required amino acid histidine, and therefore unable to grow 
and form colonies in its absence (MORTELMANS and ZEIGER, 2000). 
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When the Salmonella tester strains are grown on minimal agar plates containing 
a trace of the amino acid histidine, only those bacteria are able to form colonies, 
that revert to histidine independence (his+). 
These days the bacterial reverse mutation assay has established itself as an 
initial screen to determine the mutagenic potential of new chemicals and drugs. 
 
Salmonella
Typhimurium strain
(~108 bacteria)
100 µl 200 µl 500 µl
Testsubstance
(Bile pigments)
S9Mix
2ml Top agar
with biotin
Counting of the revertant colonies
Minimal Glucose Agar 37°C; 48h
The Ames Salmonella test [9]
 
Figure 9: Steps depicting the preincubation assay 
 
3.3 Implementation of the Ames test 
 
3.3.1 Preparation of minimal glucose agar plates: 
The outcome of every production of minimal glucose agar plates was 
approximately about 300 minimal glucose agar plates. 
Therefore, 8 1.000 mL Erlenmayer flasks were filled up with 11.25 g of Oxoid 
agar, followed by 700 mL of distilled water. The flasks were closed with a 
dabber and wrapped with a piece of aluminium foil. Together with an adequate 
amount of glucose- and Vogel-Bonner solution, kept in 250 ml Pyrex flasks, 
they were put into the autoclave and sterilised. To control the sterilisation 
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operation, an indicator sticky tape was placed on each flask (For preparations of 
the solutions see below). 
 
 
    
 
 
Picture 8: Autoclave with Erlenmayer flasks containing minimal glucose agar, Vogel-Bonner- 
and Glucose solution 
 
Before starting, sterile Petri-dishes needed to be prepared. Therefore they were 
unpacked and stacked – lid on top – in batches of 10. The casting of the plates 
was started at the bottom of each pile, by lifting the Petri-dishes above. 
After the sterilisation process had been finished, the Erlenmayer flasks and the 
other solutions were immediately placed under the laminar flow. 
Primarily 15 ml of Vogel-Bonner solution was added to each agar-containing 
Erlenmayer flask and, after shaking, 37.5 mL of glucose-solution followed. 
Afterwards the intermixture was stirred again and shortly after that the agar was 
filled into the arranged plates with an approximate thickness of 0.5 cm.  
 
 
 
      Picture 9: Erlenmeyer flasks and required solutions under 
 the laminar flow 
 
 
 
      
      Picture 10: Poured agar plates 
 
After a drying time of about 12 hours, the minimal glucose plates were repacked 
and closed firmly to avoid air inlet. The storage temperature amounted to 4°C. 
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3.3.2 Vogel-Bonner solution 
In 670 mL of distilled water at a temperature of 45 °C, 10 g of magnesium 
sulphate heptahydrate, 100 g of citric acid monohydrate, 500 g of dibasic 
potassium phosphate and 175 g of sodium ammonium phosphate tetrahydrate 
were added and dissolved. The solution was then divided in Pyrex flasks and 
sterilised after preparation and each time before use. 
3.3.3 Glucose solution (40%) 
The 40% solution was produced with 400 g of glucose, dissolved in 1.000 mL of 
boiling deionised water. Before each time of use the glucose solution was 
autoclaved. 
3.3.4 Preparation of the nutrient broth (NB) and the overnight culture 
(OVNC) 
5 g of Nutrient Broth were weighed in a 250 mL Pyrex flask, filled up with 200 
mL of deionised water and put in the autoclave. Before use, the solution needed 
to be cooled-down. Then, according to the Salmonella strain used, the NB was 
inoculated with the specific antibiotics just before starting the OVNC: 
 
Salmonella strain Antibiotics 
TA98 625 µL of Ampicillin 
TA102 
 
625 µL of Ampicillin 
156 µL of Tetracyclin 
Table 4: Strain specific antibiotics pipetted into the nutrient broth 
 
Thereof, 12 mL each were transferred into two sterile 100 mL Erlenmeyer 
flasks. To each of the flasks the particular bacterial colony (either strain TA98 or 
TA102) was taken from a master plate, added, and whirled. 
In succession, the flasks were recapped with a dabber and aluminium film and 
put into the incubator at 37°C, for 12 hours. 
During the incubation, the OVNC was continuously shaken at 55 rpm. 
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      Picture 11: Prepared OVNC in the incubator 
 
3.3.5 Ampicillin solution (0.8%) 
0.2 g of ampicillin were weighed into a capable plastic tube and mixed with 2 5 
mL of 0.2N sodiumhydroxide. Afterwards the solution was sterilised through an 
aseptic filter, and could be stored at 4°C. 
3.3.6 Tetracycline solution 
To 80 mg of tetracycline - weighed in into an adequate plastic tube – 10 mL of 
0,2N hydrochloric acid werte added. After sterilising the solution through an 
aseptic filter, it could be stored at 4°C for two weeks. 
3.3.7 Histidine solution 
0.25 g of histidine was mixed with 50 mL of deionised water and filter-sterilized. 
The solution could be stored at 4°C. 
3.3.8 Biotin solution 
Into a capable plastic tube, 6.1 mg of D-biotin were weighed in and mixed with 
50 mL of deionised water. After aseptic filter sterilisation, the solution was kept 
at 4°C. 
3.3.9 Preparation of the master plates 
For the preparation of two master plates (two per strain), 3.2 g of Oxoid agar 
was weighed into a 250 mL Pyrex flask and filled up with 200 mL of deionised 
water. The flask was put in the autoclave, together with the required amount of 
glucose- and Vogel-Bonner solution. After the sterilisation process, 4.3 mL 
Vogel-Bonner- and 10.8 mL glucose solution were added, followed by 2.17 mL 
of histidine- and 1.3 mL of biotin solution, under sterile conditions. 
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After each compound the flask was shaken to obtain a homogenous dispersion. 
The (strain specific) antibiotics are sensitive to heat, therefore the agar had to 
be cooled down before the addition. 
For strain TA98 682 µL of ampicillin were used, whereas TA102 additionally 
needed 54 µL of the tetracycline solution. 
After this step the content of the flask was mixed again.  
The agar was then ready to be poured into two sterile Petri dishes, whereupon 
the thickness of the agar in the dishes amounted to approximately 1 cm. 
The plates were left in the powered laminar flow to dehumidify for 24 hours. 
After drying, the intended bacterial strains, taken from a prepared bacterial 
overnight culture, were applied on the plates lattice-like. After another drying 
time of about 15 - 20 minutes and under sterile conditions, the master plates 
were put in the incubator at 37°C for 48 hours. 
After incubation the plates were stored at 4°C. Once inoculated, the master 
plates could be kept for either up to 2 months (TA98) or 2 weeks (TA102) 
respectively. 
3.3.10 Preparation of the top agar 
For the top agar 1.2 g of Oxoid agar and 1 g of sodium chloride were weighed in 
into a 250 mL Pyrex flask and filled up with 200 mL deionised water. 
Subsequently the agar was put in the autoclave to be ready shortly before the 
test started. Before use, 20 mL of the also autoclaved histidine-biotin solution 
were added under sterile conditions and then put into the water bath at 55°C. 
 
 
            
 
            Picture 12: Top agar and histidine-biotin solution in the autoclave 
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3.3.11 Preparation of the histidine-biotin solution 
The histidine- biotin solution consisted of 30.9 mg D-biotin and 24 mg L-
histidine which were weighed in with the laboratory scale into a weighing boat. 
Afterwards the amino acids were carefully transferred into a 250 mL Pyrex flask 
and filled up with 250 mL of deionised water. The solution was sterilised each 
time before use, and was kept at 4°C. 
 
Denotation 
Abbreviation/ 
Empirical formula 
Source 
Order 
number 
Utilisation 
Agar No 1  Lab M/Bertoni LP011P 
Plates, top 
Agar 
Ampicillin Trihydrate  Sigma A6140 
Master plates, 
OVNC 
D-Biotin C10H7NO2 Sigma B4639 Master Plates 
Dimethylsulfoxide DMSO Sigma D5879 
Frozen 
Permanents, 
solvent 
D-Glucose C6H12O6 Sigma G8270 
MG-Agar-
Plates, Master 
Plates 
Glucose-6-Phosphat Glu-6-P Sigma G7250 S9-Mix 
Potassiumchloride KCl Sigma P5405 S9-Mix 
Potassiumphosphate, 
dibasic 
K2HPO4 Sigma P3786 
Vogel-Bonner 
solution 
L-Histidine C6H9N3O2 Sigma H8125 
Top Agar, 
Master Plates 
Magnesiumchloride MgCl2·6H2O Sigma M9272 S9-Mix 
Magnesiumsulphate MgSO4·H2O Sigma M9397 
Vogel-Bonner 
solution 
Nutrient Broth No 2 
CM 67 
 Lab M/Bertoni CM067B OVNC, NB 
Sodiumammonium-
phosphate 
Na2NH2PO4·4H2O Sigma S9506 
Vogel-Bonner 
solution 
Sodiumchloride NaCl Sigma S5886 Top Agar 
Sodiumhydroxide NaOH Sigma O6203 
Ampicillin 
solution 
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Nicotineamid- 
Adeninedinucleotide-
phosphate 
NADP Sigma N0505 S9-Mix 
Phosphatebuffer PBS PAA Labor H15002 
Pre-incubation, 
S-9 Mix 
Rat liver homogenate S9 MP Biomedicals 50412 
Trials with 
metabolic 
activation 
 
Tertiary-Butyl-
hydroperoxide 
t-BOOH Sigma T3383 
Oxidative 
mutagen 
Tetracycline 
Hydrochloride 
 Sigma T3383 
Master Plates, 
OVNC 
2,4,7-Trinitro-9- 
Fluorenone 
TNFone - - 
Standard 
mutagen in the 
Ames test 
Citric acid 
monohydrate 
C6H8O 7 ·H2O Sigma C1909 
Vogel-Bonner 
solution 
2-Amino-1-Methyl-6-
Phenylimidazo[4,5-
b]Pyridine 
PhIP 
Toronto 
Scientific 
A617000 Mutagen 
Aflatoxin B1 AFB1 Sigma A6636 Mutagen 
Table 5: Index of chemicals used within the test procedures 
 
3.3.12 Characterisation of the pre-incubation test 
The workflow was performed in the following manner: 
Under sterile conditions, chronologically 500 µL of PBS buffer, 100 µL of the 
OVNC as well as 100 µL of the intended samples, here the bile pigments, were 
pipetted into sterile test tubes. If metabolic activation was necessary, the buffer 
was replaced by 500 µL of the S9-Mix. 
As soon as the first sample or the positive control respectively was added, a 
timer, set to 25 min, was started. 
As soon as the entire range of compounds had been added, the test tubes in 
the rag were stirred and then put into the incubator until the time elapsed. 
During incubation the tubes were shaken at 55 rpm at a temperature of 37°C.  
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Picture 13: Filled test tubes ready           Picture 14: Poured plates in the incubator 
for preincubation 
 
In the following, the rag was taken out and placed under the laminar flow to add 
2 mL of top agar to each of the tubes. After vortexing, the content of each test 
tube was poured and instantly dispersed on compatibly labelled minimal 
glucose agar plates. 
The plates were then dried for 25 to 30 min and subsequently stored (lid down) 
in the incubator for 48h at 37°C. 
 
All the trials implemented during the project were performed in terms of pre-
incubation practices. 
3.3.13 Positive and negative controls in use 
Acquainted mutagenic substances were used as positive controls, specifically 
for each tester strain, to reveal reversion that appears when bacteria are 
influenced by mutagens. 
Following mutagenic substances were used in the tests: 
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Strain Without metabolic 
activation 
Including metabolic 
activation 
TA98 2,4,7-Trinitro-9-Fluoroenone 
(TNFone) 
[0.0001 mg/mL] 
2-Amino-1-Methyl-6-
Phenylimidazo[4,5-b]Pyridine 
(PhIP) 
[0.1 µmol/mL] 
  Aflatoxin B1 (AFB1) [5 µg/mL] 
 
TA102 2,4,7-Trinitro-9-Fluoroenone 
(TNFone) 
[0.07 mg/mL] 
 
 Tertiary-Butyl Hydroperoxide 
(t-BuOOH) 
[0.75*10^-6 mol/plate] 
Tertiary-Butyl Hydroperoxide 
(t-BuOOH) 
[0.75*10^-6 mol/plate] 
  Aflatoxin B1 (AFB1) 
[120 µg/mL] 
Table 6: Diagnostic mutagens/positive control 
 
In order to prove the number of spontaneous revertants, negative controls 
were applied. Since the samples within the trial were dissolved in DMSO, this 
solvent was also used as the negative control. 
3.3.14 Preparation of the S9-Mix 
Since bacteria do not have a cytochrome-based P450 metabolic oxidation 
system, like humans and lower animals, an exogenous mammalian organ 
activation system needed to be added. Therefore the S9-Mix, representing an 
enzymatic mixture made from rat liver homogenate, was applied in the in vitro 
test. 
The metabolic activation system for a maximum of 100 plates consisted of:  
19.75 mL sterile deionised water, 25 mL PBS buffer (without Ca and Mg), 1 mL 
MgCl2/KCl solution, 2 mL NADP solution as well as 250 µL glucose-6-
phosphate solution. All compounds were pipetted into a 50 mL centrifuge tube, 
at last the rat liver homogenate, which had been stored at -80°C, was added. 
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It is necessary to prepare the S9-Mix freshly just before the beginning of the 
test, and to cool it constantly on ice during the experiment, since the solution 
contains highly susceptible enzymes; the mix is applicable for a maximum of 60 
min. 
3.3.15 Preparation of the glucose-6-phosphate (304 mg/mL) 
1 g of glucose-6-phosphate was solved in 3.289 mL of deionised water. Then, 
the solution was aseptically filtered and pipetted in portions of 260 µL each, into 
cryo tubes. The prepared quantity represents the volume needed for the mixture 
of one S9-Mix. 
The tubes were stored at – 20°C. 
3.3.16 Preparation of the MgCl2/KCl solution 
61.5 g of KCl as well as 40.7 g of MgCl2 were dissolved in 50 mL of deionised 
water. The solution was sterilised in the autoclave. 
3.3.17 Preparation of the NADP solution (0.135 g/2mL) 
1g of NADP was dissolved in 14.814 mL of deionised water. The solution was 
then sterilised through an aseptic filter. Cryo tubes each containing 2 mL of the 
NADP solution were frozen at -20°C. The portion size was consistent with the 
amount needed for each S9-mix.  
3.3.18 Colony counting 
The plates were incubated for 48 hours, and with a with a colony-meter, the 
colonies were counted. To enhance the detection of the white spots, it is 
beneficial to place the plates onto a flat lamp. The results were expressed as 
revertant colonies per plate.  
Mutagenic tendencies were existent, if the number of revertants on a sample-
plate exceeded the double negative control. 
 
 
 
           Picture 15: Counted plate 
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3.4 Statistical analysis 
The data were entered into Microsoft Excel and that followed transferred to 
Sigmastat (Systat Software, Inc. ver.17.0). First the Kruskal-Wallis one-way 
analysis on ranks was applied to ensure that the data are normally distributed. 
Further arithmetic means and standard deviations were determined. 
To figure out whether a significance can be found, the bile pigment’s different 
concentrations were tested in comparison to the positive control (anti-mutagenic 
testing) and the negative control (mutagenic testing) respectively. For this 
purpose the one-way analysis of variance (ANOVA) was applied. 
In order to identify the post-hoc differences between the revertants formed at 
different concentrations and the positive and the negative control data, the 
Bonferroni and the Tukey B tests were performed. 
A p-value <0.05 was considered significant. 
 
For a further interpretation of the test results, the data were divided in 
classification groups according to Mortelmans et al. (2000): 
 
• Mutagenic: 
If a compound produces a reproducible, dose-related increase in the number of 
revertant colonies in one ore more strains or when their numbers of His+ 
revertant colonies exceed doubled negative control counts, it is considered a 
mutagen. 
 
• Weak mutagen: 
If the tested substances produce a reproducible, dose-related increase in the 
number of His+ revertants in one ore more strains but the number of the 
revertants is not double the background number of colonies. 
 
• Inconclusive: 
If substances cannot be clearly assigned as mutagenic or a non-mutagenic, the 
results are classified as inconclusive. 
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• Non-mutagenic: 
 
The compounds are classified as non-mutagenic if no concentration-dependent 
increase in the number of revertant colonies is observed in at least two different 
experiments. 
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4. Results of the trials and discussion 
 
Bilirubin dimethyl ester and biliverdin dimethyl ester were tested in two strains of 
Salmonella typhimurium (TA98, TA102) in order to detect whether they could 
modulate spontaneous or induced genotoxicity. When the bile pigments were 
tested alone, without a positive control, they were neither mutagenic nor did 
they cause toxicity in the two Salmonella strains used (p<0.001, see chapter 
6.4). In the following, only that data of the anti-mutagenic experiments that show 
a significant difference between the distinct tested concentrations of the bile 
pigments and the positive control will be presented in diagrams or histograms.  
The mentioned ID50 displays the amount of bile pigments in µmol that is 
necessary to inhibit 50% of the added mutagen. 
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4.1 TA98 – anti-mutagenic testing 
 
4.1.1 2,4,7 trinitrofluoreneone induced mutagenicity 
 
2,4,7 trinitrofluorenone (TNFone) induced genotoxicity was used to test the 
possible anti-mutagenic effects of bile pigments bilirubin dimethyl ester and 
biliverdin dimethyl ester in the absence of metabolic activation. The first 3 
concentrations (2 to 0.5 mol) exhibited significant difference to the positive 
control (p<0.05). All compounds inhibited the TNFone induced genotoxic effects 
in a dose dependent manner (Figure 10). The ID50 for BRDME amounted to 
1.32 µmol, the one for BVDME 1.70 µmol.  
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Figure 10: The modulatory effects of bilirubin dimethyl ester (BRDME) and biliverdin dimethyl 
ester (BVDME) on TNFone induced genotoxicity in TA98 Salmonella typhimurium (n=6). 
 
 
 
 
* * * 
*  p<0.05 
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4.1.2 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine induced 
mutagenicity  
 
For testing the capacity of BRDME and BVDME to inhibit mutagenicity induced 
by PhIP, metabolic activation was applied. Figure 11 illustrates that the curves 
of both compounds proceeded below the 50 % inhibition line. The whole 
concentration range from 0.01 to 2 µmol significantly reduced the number of 
His+ revertants (p<0.001). 
0
10
20
30
40
50
60
70
80
90
100
210,50,10,050,01
Bile pigment dose (umol/plate)
Pe
rc
en
ta
ge
 
o
f p
o
si
tiv
e 
co
n
tr
o
l (%
)
BRDME BVDME
 
Figure 11: The modulatory effects of BRDME and BVDME on PhIP induced genotoxicity in 
TA98 Salmonella typhimurium (n=6). All concentrations are significant different to the positive 
control (p<0.001). 
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4.1.3 Aflatoxin B1 induced mutagenicity 
 
AFB1 induced genotoxicity was used to investigate the possible anti-mutagenic 
effects of the bile pigments including metabolic activation. The entire 
concentration range as well for BRDME as for BVDME exhibited a significant 
difference to the positive control (p<0.001). The ID50 of BVDME with 0.73 µmol 
was clearly lower than the one of BRDME, requiring 2.20 µmol to inhibit 50% of 
the tested mutagen (Figure 12). 
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Figure 12: The modulatory effects of BRDME and BVDME on AFB1 induced genotoxicity in 
TA98 Salmonella typhimurium (n=6). All concentrations are significant different to the positive 
control (p< 0.001). 
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4.2 TA102 – anti-mutagenic testing 
 
4.2.1 2,4,7 trinitrofluorenone induced mutagenicity 
 
When TNFone caused mutation in the TA102 strain, without the application of 
the S9-fraction, BRDME and BVDME inhibited this response in a dose 
dependent manner. Both bile pigments significantly reduced the number of His+ 
revertants in each tested concentration range and, moreover, in Figure 13 it is 
apparent that the curves of the two compounds ran along or even below the 
50% line. The ID50 of BRDME amounted to 0.19 µmol, the one of BVDME 0.03 
µmol. 
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Figure 13.: The modulatory effects of bile pigments on TNFone induced genotoxicity in TA102 
Salmonella typhimurium (n=6). All concentrations are significant different to the positive control 
(p<0.001). 
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4.2.2 2- Aflatoxin B1 induced mutagenicity 
 
AFB1 induced genotoxicity was used to test the possible anti-mutagenic effects 
of the bile pigments BRDME and BVDME in the presence of metabolic 
activation. In this condition, both compounds significantly reduced the number 
of His+ revertants (p<0.001). In any tested concentration an anti-mutagenic 
impact of the bile pigments could be demonstrated (Figure 14). 
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Figure 14: The modulatory effects of bile pigments on AFB1 induced genotoxicity in TA102 
Salmonella typhimurium (n=3). All concentrations are significant different to the positive control 
(p<0.001). 
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4.2.1 TA102 – antioxidant testing 
4.2.1.1 t-BuOOH induced pro-oxidative effects without S9 
 
With t-BuOOH possible antioxidant effects of bile pigments were tested. When 
metabolic activation was absent, BRDME and BVDME inhibited t-BuOOH 
induced mutagenic response only to a partly significant extent. BRDME reduced 
the number of His+ revertants significantly at 1 and 0.5 µmol and BVDME at 1 
and 0.1 µmol (see table 7). 
 
Concentration % of Positive Control 
BRDME 
% of Positive Control 
BVDME 
2 91.9 ± 6.6 89.05 ± 3.6 
1 79.8*± 8.8  79.25 ± 6.4 
0.5 71.3* ± 3.35 85.5 ± 7.75 
0.1 80.15 ± 7.15 71.3* ± 5.3 
0.05 90.15 ± 5.9 96.15 ± 7.1 
0.01 83.85 ± 7.1 82.45* ± 10.95 
 
Table 7: Averaged percentages of the positive control values of BRDME and BVDME tested 
with t-BuOOH without metabolic activation; (* p<0.05) ± the averaged percentages of standard 
deviations of BRDME and BVDME tested with t-BuOOH without metabolic activation. 
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4.2.1.2 t-BuOOH induced pro-oxidative effects with S9 
 
In the presence of metabolic activation, the effects of the bile pigments 
concerning their ability to inhibit t-BuOOH induced mutation, improved 
considerably. Both compounds exhibited a significant anti-mutagenic effect on 
revertant formation (p<0.05), (Figure 15). 
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Figure 15: The modulatory effects of bile pigments on t-BuOOH induced genotoxicity in TA102 
Salmonella typhimurium with metabolic activation (n=6). All concentrations are significant 
different to the positive control (p<0.05). 
 
 
4.3 Summary of mutagenic modulation 
In Table 9 a summary of the bile pigments capacity to modulate genotoxicity in 
the TA98 and TA102 bacteria is presented. The concentrations that inhibit 
mutagenicity to 50% of the positive control (ID50), the percentage anti-
mutagenic response at the highest common dose (0.5 µmol/plate; I0.5) and the 
highest respective dose tested (Imax) are presented to facilitate the identification 
of the relative anti-mutagenic effects of the bile pigments. 
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Strain Mutagen 
(mol/plate) 
S9 Compound ID50 
(µmol) 
ID75 
(µmol) 
I0.5 
(%) 
Imax 
(%) 
His+ 
BRDME 
 
1.32 2.63 58.05 41 TA98 2,4,7 
TNFone 
(3.17*10-11) 
- 
BVDME 1.70 3.38 70.25 50.1 
422 
 
BRDME - 2.93 32.15 29.35 TA98 PhIP 
(0.1*10-7) 
+ 
BVDME -  40.5 44.3 
442 
BRDME 2.20 - 48.25 54.3 TA98 AFB1 
(1.22*10-8) 
+ 
BVDME 0.73 - 50.05 50.56 
295.5 
BRDME 0.19 2.62 44.9 35.35 TA102 2,4,7 
TNFone 
(2.22*10-8) 
- 
BVDME 0.03 3.35 45.75 27.2 
1217.5 
BRDME - - 51.7 66.6 TA102 AFB1 
(2.9*10-7) 
+ 
BVDME - - 65.6 69.1 
1041 
 
BRDME - - - 91.9 TA102 t-BuOOH 
(0.75*10-6) 
- 
BVDME - - - 89.05 
1259 
BRDME - - - 75.05 TA102 t-BuOOH 
(0.75*10-6) 
+ 
BVDME - - - 56.85 
1229 
Table 8: The modulatory effects of bile pigments on genotoxicity in the TA98 and TA102 
Salmonella strains 
 
ID50, dose of compound required for 50% inhibition; ID75, dose of compound required for 75% 
inhibition; I0
.5, percent inhibition at 0.5 µmol/plate; Imax, percent inhibition at the maximum dose 
tested; His+, mean number of histidine positive revertant colonies in the positive control plates of 
two experiments; BRDME, BVDME. 
 
4.4 Mutagenic testing 
 
To assure that the bile pigments do not provoke mutations on their own, 
mutagenic experiments were conducted. In these, some of the mutagens could 
be taken together, as the positive control was not added to the test tubes which 
contained the bile pigments. 
For the statistical analysis the results of the his+ revertants were compared to 
the 2nd fold negative control. Since, the complete achieved results appeared 
with a significant difference to the 2nd fold negative control values (p<0.001), 
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this implied a significant difference to the positive control as well and was 
therefore not tested separately. 
4.4.1 Mutagenic testing - strain TA98 
 
4.4.1.1 Mutagenic testing with TNFone 
 
The data shown in Figure 16 illustrates, that the curves of BRDME and BVDME 
did not even reach the negative control values and were therefore definitely not 
mutagenic.  
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Figure 16: Mutagenic testing of BRDME and BVDME with TNFone in strain TA98 (n=3). 
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4.4.1.2 Mutagenic testing with AFB1 and PhIP 
 
When testing the bile pigments bilirubin dimethyl ester and biliverdin dimethyl 
ester with AFB1 and PhIP, interestingly the diagram’s balks of bilirubin dimethyl 
ester increased with the concentration range, amounting to about 120 % of the 
negative control at 2 µmol/plate. BVDME, in contrast, proceeded continuously 
below the negative control (Figure 17). 
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Figure 17: Mutagenic testing of BRDME and BVDME with AFB1 and PhIP in strain TA98 (n=3). 
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4.4.2 Mutagenic testing – strain TA102 
 
4.4.2.1 Mutagenic testing with TNFone and t-BuOOH (without 
metabolic activation) 
 
The curves of both compounds were below the negative control (Figure 18), 
thus suggesting that the bile pigments do not induce mutagenicity. 
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Figure 18: Mutagenic testing of BRDME and BVDME with TNFone and t-BuOOH (without 
metabolic activation) in strain TA98 (n=3). 
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4.4.2.2 Mutagenic testing with AFB1 and t-BuOOH 
 
Also for AFB1 and t-BuOOH, the his+ revertants did not exceed the negative 
control and therefore it can be said that bilirubin dimethyl ester or biliverdin 
dimethyl ester alone did not provoke any mutation (Figure 19). 
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Figure 19: Mutagenic testing of BRDME and BVDME with AFB1 and t-BuOOH in strain TA102, 
including metabolic activation (n=3). 
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4.5 Discussion 
 
As already mentioned in the literature survey (see chapter 4.2.2 and 4.2.3) the 
antioxidant capacity of the bile pigments is well established, but explicit data on 
their anti-mutagenic potential is lacking. 
In this thesis, the Ames Salmonella test was chosen, in order to consider the 
impact of bile pigments’ in the presence of genotoxic compounds which 
possess different three-dimensional conformations (Figures 5-8). In addition, 
the bile pigment’s antioxidant effects were tested. 
 
The four different tested mutagens in this thesis were t-BuOOH, TNFone, PhIP 
and AFB1, whereas actually and to the best of our knowledge, assumptions for 
the anti-mutagenic potential of the bile pigments is only existent for t-BuOOH 
and TNFone. 
 
In order to evaluate the findings in sequence the experiments with t-BuOOH will 
be examined first. 
t-BuOOH, an organic hydroperoxide, was selected in order to test the multi-
modal mechanism of action of bile the pigments in strain TA102, which is 
susceptible to oxidative stress induced mutation (LEVIN et al., 1984). t-BuOOH, 
which causes DNA damage in vitro (EPE et al., 1990) via the generation of 
reactive oxygen species, including alkoxyl radicals (MINOTTI et al., 1986), was 
used to promote mutation. Bile pigments possess the ability to inhibit peroxyl 
radical chain reactions in lipids via a hydrogen donation mechanism (STOCKER 
et al., 1987a). As alkoxyl and peroxyl radicals share similar structures it is 
thinkable that bile pigments are also efficient alkoxyl radical scavengers, 
providing a mechanism whereby bile pigments could interfere with t-BuOOH 
induced DNA damage (MAHLER et al., 2001).  
With the results of this thesis it could be shown that BRDME and BVDME 
attenuated t-BuOOH induced mutation, even though the effects appeared not 
too strong. 
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Without metabolic activation, both bile pigments inhibited the positive control to 
an extent of about 10 to 20% (Table 7 and 8), while in the presence of 
enzymatic catalysis the results improved and amounted to a 25% - 45% 
inhibition (Figure 15). 
An explanation for this observation could be provided by Stocker in 2004, who 
detected that bilirubin is able to neutralise two radicals via initial hydrogen atom 
donation, forming a bilirubin radical, which binds to another radical forming a 
non-radical complex. In contrary, biliverdin can only accept one electron with 
the formation of a resonance stabilised biliverdin radical complex (STOCKER et 
al., 1987b). 
 
The question about what is accountable for the anti-mutagenic effects of the bile 
pigments leaded to their structural conformation. 
 
With reference to Bulmer et al. (2007), it is known that unconjugated bilirubin 
and biliverdin inhibit the mutagenic effects of TNFone. This is founded on their 
acquirement to affect the ability of TNFone to disrupt DNA structure. Our results 
support this observation, though the difference between the anti-mutagenic 
potential within the two pigments was not clearly attachable. In strain TA98, 
BRDME showed slightly stronger effects than BVDME. For the former an ID50 of 
1.32 µmol was calculated, while the ID50 of biliverdin dimethyl ester amounted 
to 1.70 µmol.  
In strain TA102 the results appeared converse, producing an ID50 of 0.03 µmol 
for BVDME and 0.19 µmol for BRDME.  
 
Regarding PhIP and Aflatoxin B1, particularly hazardous mutagens commonly 
occurring in food products, it can only be speculated about the reasons for the 
bile pigment’s anti-mutagenic effects since data is lacking.  
Most probably also these prosperities may be due to similarities within the 
structures of the bile pigments and the mutagens, or maybe the explanation is 
once more provided by the hydrogen donation system mentioned before. 
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Interestingly, in our trials bilirubin dimethyl ester’s 3D ridge tile conformation 
(Figure 4) most effectively inhibited PhIP (strain TA98, Figure 5) whereas 
biliverdin dimethyl ester (Figure 4) most effectively inhibited TNFone (strain 
TA102, Figure 7). 
 
Although the data presented cannot be transferred to the in vivo condition, the 
presumption of the bile pigment’s anti-mutagenic and antioxidative potential in 
strains TA98 and TA102 could be strenghtened again.  
It is well known that the information value of the Ames Salmonella assay is 
limited due to inaccuracies in counting the revertant colonies, especially when 
exceeding 1500, and various other circumstances that can hardly be influenced.  
E.g. the season, affecting the room temperature and hence resulting in a 
reduced cooling capacity of the fridge. But also chemicals, for instance different 
S9 charges, may exert considerable influence on the results.  
 
The anti-mutagenic effects of the bile pigments bilirubin dimethyl ester and 
biliverdin dimethyl ester tested in the course of this thesis were definitely 
crowned with success as in the complete testing series, the compounds 
collectively achieved anti-mutagenic and antioxidant effects respectively. 
Moreover, this could be confirmed with the mutagenic tests in which the bile 
pigments had never exceeded the 2fold negative control values. 
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5. Conclusion 
 
The aim of this study was a further investigation of the possible anti-mutagenic 
and antioxidant properties of bile pigments. For this purpose it was explored 
whether bilirubin dimethyl ester or biliverdin dimethyl ester could prevent DNA 
mutation in the Salmonella typhimurium strains TA98 and TA102. 
Strain TA102 was included to probe the potential antioxidant capability of the 
pigments, as repeated evidence for this hypothesis is existent, e.g. by Stocker 
(2004).  
 
Besides, the carcinogen PhIP, belonging to the group of heterocyclic aromatic 
amines, and AFB1, a well known and often occurring consequence of spoiled 
food, were implicated. As far as known, there do not exist any other findings 
with these two substances in the Ames test, investigating the bile pigments’ 
anti-mutagenic properties.  
On the contrary, the positive impact of the compounds in inhibiting his+ 
revertants induced by TNFone and t-BuOOH, already published by Bulmer et al. 
(2007), could be confirmed. 
 
For all of the four mutagens tested in the course of this thesis, the two bile 
pigments exerted a considerable anti-mutagenic effect in strain TA98, as well as 
in TA102. Moreover, it was verified that none of the compounds was mutagenic 
itself, supporting their anti-mutagenic and antioxidant potential and therefore 
their postulated physiological relevance. 
 
In strain TA98 the lines of both bile pigments proceeded continuously below the 
50% line at PhIP induced mutation (Figure 11). A similar outcome could be 
gained when AFB1 was applied to induce mutagenic response: the curves of 
BRDME and BVDME predominantly lay below the 50% line (Figure 12). 
Interestingly, at higher concentrations, at 1 and 2 µmol respectively, the number 
of mutants was slightly or markedly above this level. 
Using TNFone as mutagen, a clear dose dependent decrease of the his+ 
revertants could be observed (Figure 10), though all in all the anti-mutagenic 
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effects achieved by the bile pigments were rather weak until a concentration 
range of approximately 0.5 µmol or higher. At this amount 30% - 40% of the 
positive control could be inhibited by BVDME and BRDME respectively. At the 
highest concentration of 2 µmol, both compounds passed the 50% line, BRDME 
even gained a 60% inhibition of the positive control. 
 
In strain TA102 the most auspicious anti-mutagenic results could be reached for 
TNFone, presenting a continuous decrease in revertants. From 0.5 µmol 
BRDME and BVDME inhibited the TNFone induced mutation to an extent of 
more than 50%, reaching the maximum at 73% provoked by BVDME at the 
highest concentration of 2 µmol (Figure 13).  
For AFB1 induced genotoxic response, the bile pigments’ effectiveness in 
inhibiting mutation ranged between 35% and 45% for BRDME and between 
25% and 35% for BVDME respectively. 
 
Regarding the antioxidative capacity of the two compounds tested with t-
BuOOH in strain TA102, especially the outcomes of the experiments conducted 
without metabolic activation showed that the impact of the bile pigments was 
weak. As for both pigments, the inhibitory effects were only between 10% - 20% 
(Table 7). 
In the presence of enzymatic catalysis, a 45% inhibition of BRDME and BVDME 
could be revealed at the lowest concentration range (0.01 µmol). Interestingly, 
at least for BRDME the higher concentrations of the pigment were linked with 
an augmented number of revertants, achieving only about 25% of inhibition of 
the positive control value at the highest concentration of 2 µmol (Figure 14), 
whereas BVDME seemed to appear rather independent of the bile pigment 
dose.  
 
It was hypothesised that the bile pigments would inhibit mutation caused by 
mutagens that shared similarities in their respective three dimensional 
structures. And, moreover, the bile pigments were considered to be able to 
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inhibit mutation caused by tertiary butyl hydroperoxide, due to their well known 
antioxidant potential.  
Regarding the relevance of the structural similarity, the existent results could 
only partially be confirmed.  
Referring to a study of Bulmer et al. (2007) it was evidenced that unconjugated 
bilirubin, exhibiting a non planar structure, is more effective in inhibiting 
mutation caused by 2,4,7 trinitrofluorenone, which is also a non planar 
compound and that biliverdin stronger inhibited 2-aminofluorene, a planar 
compound. Indeed an anti-mutagenic potential could be observed in the tests 
conducted for this thesis, but this applied as well for the non planar BRDME as 
for the planar BVDME, since no mentionable differences in the effectiveness 
between the two compounds in inhibiting TNFone induced mutation could be 
observed. 
 
Also for tertiary butyl hydroperoxide, independent whether experiments were 
conducted with or without metabolic activation, the effectiveness of bilirubin 
dimethyl ester and biliverdin dimethyl ester appeared without remarkable 
distinctions (Table 7, Figure 15). The results were related to their antioxidant 
potential and suggest that the bile pigments act as ‘intercepting’ molecules with 
the capacity to bind mutagens and prevent them from rearranging DNA 
structure, additionally to preventing mutation, via oxidative modification. 
Moreover, it can be assumed that bilirubin might exert anti-mutagenic effects at 
physiological concentrations, seen in the circulation. Further, bilirubin 
compounds could incept mutagens at physiological concentrations seen in the 
intestine.  
Therefore, the possibility of supplying bile pigments via oral administration could 
emerge a pioneering success. 
 
However, at present this cannot be verified due to the fact that bilirubin 
becomes potentially toxic in higher ranges of concentrations.  
To conclude, the findings obtained in the course of this thesis provided 
consistent evidence for the anti-mutagenic and antioxidant potential of the bile 
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pigments. As in vitro data is rising, the next step will be to gain more insight in 
the compounds’ in vivo behaviour to reinforce the existent and auspicious 
evidence of the bile pigment’s beneficial properties.  
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6. Summary 
 
In order to reveal the anti-mutagenic and antioxidant properties of the two 
synthetic bile pigments bilirubin dimethyl ester and biliverdin dimethyl ester, the 
Ames Salmonella assay, applying the preincubation test, was chosen.  
The Ames Salmonella/microsome mutagenicity assay is a short-term bacterial 
reverse mutation assay which was specifically designed to detect the mutagenic 
potential of various chemical substances but which otherwise also exposes 
possible beneficial effects of the investigated compounds against genotoxic 
DNA alterations.  
 
In this thesis bilirubin dimethyl ester and biliverdin dimethyl ester were tested for 
their potential to inhibit mutagenicity induced by 2,4,7-TNFone, 2-Amino-1-
Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP), Aflatoxin B1 and the oxidizing 
agent tertiary-butyl hydroperoxide in Salmonella typhimurium strains TA98 and 
TA102. To investigate a possible dose dependency, the following concentration 
ranges were tested: 0.01; 0.05; 0.1; 0.5; 1; 2 µmol/plate.  
 
The achieved results give reason to the evident anti-mutagenic potential of 
BRDME and BVDME, since in every conducted test an inhibition of induced 
mutagenicity could be accomplished. A dose dependency became particularly 
apparent when TNFone was applied as a mutagen, but especially in strain 
TA98 the anti-mutagenic capacity of the two bile pigments against PhIP and 
AFB1 were prominent. 
The potential to defend t-BuOOH mediated oxidative mutations was existent 
with and without the presence of metabolic activation, but turned out to be 
considerably stronger with the application of the S9-fraction. 
To conclude, this study confirmed the anti-mutagenic and antioxidant potential 
of the bile pigments. However, the mechanisms that account for their ability to 
inhibit induced mutagenicity is still not fully understood. More knowledge about 
these processes is essential to explore the therapeutic potential of these 
promising compounds. 
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7. Zusammenfassung 
 
Ziel dieser Studie war es sowohl das antimutagene als auch das antioxidative 
Potential der zwei synthetisch hergestellten Gallenfarbstoffe Bilirubin Dimethyl 
Ester und Biliverdin Dimethyl Ester aufzuzeigen. Zu diesem Zweck wurde der 
Ames Salmonella Mutagenitätstest herangezogen, der eine rasche und 
verhältnismäßig kostengünstige Möglichkeit darstellt um das erbgutverändernde 
Potential von chemischen Substanzen (z.B. Medikamente und Pestizide) 
aufzudecken bzw. liefert dieser Hinweise auf Substanzen die möglicherweise 
DNA-schützende Effekte aufweisen.  
 
Im Zuge dieser Arbeit wurden das antimutagene Potential von Bilirubin Dimethyl 
Ester und Biliverdin Dimethyl Ester gegenüber 2,4,7 TNFone, 2-Amino-1-
Methyl-6-Phenylimidazo[4,5-b]Pyridin (PhIP), Aflatoxin B1 und dem oxididativ 
wirksamen Tertiär Butyl Hydroperoxid in den Salmonella typhimurium Stämmen 
TA98 und TA102 untersucht. Um zusätzlich auf eine mögliche dosisabhängige 
Wirkungsweise der Gallenfarbstoffe schließen zu können wurden folgende 6 
Konzentrationsstufen (in µmol/Platte) bei den Tests inkludiert: 0,01; 0,05; 0,1; 
0,5; 1 und 2.  
In jedem der durchgeführten Experimente konnte die induzierte Mutation, ohne 
wesentliche Unterschiede zwischen den beiden getesteten Substanzen, 
inhibiert werden, was einen weiteren Hinweis sowohl hinsichtlich des 
antimutagenen als auch des antioxidativen Potentials der Gallenfarbstoffe 
darstellt. Eine Dosisabhängigkeit wurde besonders bei den Tests mit TNFone 
deutlich, wobei die stärksten antimutagenen Effekte der Gallenfarbstoffe im 
Bakterienstamm TA98 bei PhIP und Aflatoxin B1 erreicht werden konnten. Die 
Fähigkeit der Ester t-BuOOH induzierte Mutationen zu verhindern konnte 
sowohl mit als auch ohne metabolischer Aktivierung belegt werden, wobei 
Erfolge mit dem S9-Mix wesentlich deutlicher ausfielen. 
 
Wesentliches Ziel für die Zukunft ist es die Mechanismen der antimutagenen 
Wirkungsweise der Gallenfarbstoffe soweit zu verstehen um das therapeutische 
Potential dieser Substanzen ausschöpfen zu können. 
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9.1 TA98 
 
9.1.1 Single revertant numbers for TA98 
 
Mutagen Concentration (µmol/plate) 
TNFone [0.001 mg/mL) TEST 1 2 1 0.5 0.1 0.05 0.01 
BRDME 214 286 287 450 476 484 
 158 220 275 473 465 527 
 220 265 334 455 455 476 
Mean 197 257 299 459 465 496 
Standard deviation (sd) 34.2 33.7 31.2 12.1 10.5 27.4 
BVDME 264 246 375 418 546 473 
 297 281 382 451 521 428 
 242 274 322 407 558 532 
Mean 268 267 360 425 542 478 
Standard deviation (sd) 27.7 18.5 32.8 22.9 18.9 52.2 
TNFone [0.001 mg/mL] TEST 2  
BRDME 130 155 169 368 451 543 
 210 168 206 315 450 505 
 105 164 213 335 451 476 
Mean 148 162 196 339 451 508 
Standard deviation (sd) 54.8 6.7 23.6 26.8 0.6 33.6 
BVDME 171 195 231 426 530 488 
 163 197 223 346 541 381 
 151 207 261 293 447 293 
Mean 162 200 238 355 506 387 
Standard deviation (sd) 10.1 6.4 20.0 67.0 51.4 97.7 
PhIP [0.1 µmol/mL]+S9 TEST 1  
BRDME 124 120 152 120 231 205 
 121 133 171 146 142 170 
 118 145 159 157 221 197 
Mean 121 133 161 141 198 191 
Standard deviation (sd) 3.0 12.5 6.9 19.0 48.8 18.3 
BVDME 218 241 187 222 263 159 
 237 188 254 201 250 199 
 232 207 214 223 216 118 
Mean 229 212 218 215 243 159 
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Standard deviation (sd) 9.8 26.9 33.7 12.4 24.3 40.5 
PhIP [0.1 µmol/mL]+ S9 TEST 2  
BRDME 148 124 116 174 128 119 
 131 110 129 - 130 112 
 123 112 127 - 124 - 
Mean 134 115 124 174 127 116 
Standard deviation 12,8 7,6 7 0 3,1 4,9 
BVDME 154 183 116 196 130 150 
 172 128 - 195 136 143 
 169 169 171 140 172 117 
Mean 165 160 144 177 146 137 
Standard deviation 9.6 28.6 38.9 32.0 22.7 17.4 
 
AFB1 [5 µmol/plate]+ S9 TEST 1  
BRDME 202 243 129 142 137 156 
 135 191 153 122 128 142 
 142 175 139 137 146 136 
Mean 160 203 140 134 137 145 
Standard deviation (sd) 36.8 35.6 12.1 10.4 9.0 10.3 
BVDME 162 101 159 104 121 128 
 121 86 112 127 69 118 
 157 64 107 90 77 127 
Mean 147 94 126 107 89 124 
Standard deviation (sd) 22.4 10.6 28.7 18.7 28.0 5.5 
AFB1 [5 µmol/plate]+ S9 TEST 2  
BRDME 148 179 163 109 138 108 
 195 207 145 132 116 104 
 140 202 126 96 118 102 
Mean 161 196 145 112 124 105 
Standard deviation (sd) 29,7 14,9 18,5 18,2 12,2 3,1 
BVDME 161 115 182 103 119 133 
 152 125 171 122 107 129 
 144 113 159 113 126 114 
Mean 152 118 171 113 117 125 
Standard deviation (sd) 8.5 6.4 11.5 9.5 9,6 10 
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9.1.2 Positive control values TA98 
 
Mutagen Positive 1 Positive 2 Positive 3 Mean sd 
TNFone Test 
1 
470 452 520 481 35,2 
TNFone Test 
2 
353 381 355 363 15,2 
PhIP Test 1 527 463 481 490 33,0 
PhIP Test 2 323 425 433 394 61,3 
AFB1 Test 1 162 291 284 288 4,9 
AFB1 Test 2 260 328 321 303 37,4 
 
9.1.3 Negative control values TA98 
 
Mutagen Neg 1 Neg 2 Neg 3 Neg 4 Neg 5 Neg 6 Mean sd 
TNFone 
Test 1  
37 37 45 50 43 34 41 6,0 
TNFone  
Test 2 
88 81 61 84 105 86 84 14.1 
PhIP 
Test 1 
62 52 51 57 59 64 58 5.2 
PhIP  
Test 2 
73 80 70 70 70 67 72 4.5 
AFB1  
Test 1 
47 63 61 44 47 41 
 
51 9.2 
AFB1  
Test 2 
49 51 52 55 48 42 50 4.4 
 
9.1.4 No treatment values TA98 
 
Mutagen No. of 
revertants 
No. of 
revertants 
No. of 
revertants 
Mean sd 
TNFone 417 425 434 425 8.5 
PhIP + S9 349 385 422 385 36.5 
AFB1 + S9 123 151 162 145 20.1 
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9.2 TA102 
 
9.2.1 Single revertant numbers for TA102 
 
Mutagen Concentration (µmol/plate) 
TNFone [0.07 mg/mL) TEST 1 2 1 0.5 0.1 0.05 0.01 
BRDME 488 505 620 571 704 700 
 505 542 624 759 637 673 
 514 567 633 742 - 551 
Mean 502 538 626 691 671 641 
Standard deviation (sd) 13.2 31.2 6.7 104.0 47.7 79.4 
BVDME 221 - 711 672 547 583 
 410 644 637 567 567 581 
 - 643 597 - 552 587 
Mean 316 644 648 620 555 584 
Standard deviation (sd) 133.6 0.7 57.8 74.2 10.4 3.1 
TNFone [0.07 mg/mL] TEST 2  
BRDME 440 540 469 632 543 612 
 328 375 484 653 595 545 
 321 422 460 682 573 602 
Mean 363 446 471 656 570 586 
Standard deviation (sd) 66.8 85.0 12.1 25.1 26.1 36.1 
BVDME 333 481 473 521 444 600 
 341 430 492 602 591 712 
 330 - 449 555 476 612 
Mean 335 456 471 559 504 641 
Standard deviation (sd) 5.7 36.1 21.5 40.7 77.3 61.5 
AFB1 [120 µg/mL]+ S9 TEST 1  
BRDME 613 656 474 501 581 546 
 700 725 488 555 688 783 
 769 500 653 454 591 744 
Mean 694 627 538 503 620 691 
Standard deviation (sd) 78.2 115.3 99.6 50.5 59.1 127.1 
BVDME 683 779 635 739 703 672 
 735 851 689 789 760 579 
 742 882 726 752 729 637 
Mean 720 837 683 760 731 629 
Standard deviation (sd) 32.2 52.8 45.8 25.9 28.5 47.0 
 
9. APPENDIX 85 
 
 
 
t-BuOOH [0,75*10^-6 mol/plate] 
+ S9 TEST 1  
 
BRDME 988 862 - 572 538 658 
 981 714 742 581 996 635 
 861 537 724 788 768 969 
Mean  943 788 733 647 767 663 
Standard deviation (sd) 71.4 104.7 12.7 122.2 229.0 30.8 
BVDME 635 620 525 572 - 922 
 621 609 522 420 768 - 
 731 603 525 - 624 - 
Mean 662 611 524 496 696 922 
Standard deviation (sd) 59.9 8.6 1.7 107.5 101.8 0 
t-BuOOH [0,75*10^-6 mol/plate] 
+ S9 TEST 2  
 
BRDME 880 835 743 935 782 610 
 874 745 772 912 617 652 
 - 700 751 714 481 455 
Mean 877 760 755 854 627 572 
Standard deviation (sd) 4.2 68.7 15.0 121.5 150.7 103.8 
BVDME 736 863 818 666 562 783 
 721 961 880 760 419 835 
 - 739 834 435 682 688 
Mean 729 854 844 620 554 809 
Standard deviation (sd) 10.6 111.3 32.2 167.2 131.7 36.8 
t-BuOOH [0.75*10^-6 mol/plate] 
- S9 TEST 1 
 
BRDME 1091 1081 982 928 992 104
5 
 1060 993 972 1044 983 107
3 
 - 883 1033 822 966 912 
Mean 1076 986 996 931 980 101
0 
Standard deviation (sd) 21.9 99.2 32.7 111.0 13.2 86.0 
BVDME 1293 1025 1125 998 1002 102
2 
 1193 1121 1248 936 1103 105
3 
 1152 953 1002 893 - 898 
Mean 1213 1033 1125 942 1053 991 
9. APPENDIX 86 
Standard deviation (sd) 72.5 84.3 123.0 52.8 71.4 82.0 
t-BuOOH [0,75*10^-6 mol/plate] 
- S9 TEST 2 
 
BRDME 1320 976 740 1017 1468 113
3 
 1326 921 - 1141 1219 116
7 
 1073 1157 815 1110 1218 - 
Mean 1240 1018 778 1089 1302 109
8 
Standard deviation (sd) 144.4 123.5 53.0 64.5 144.0 92.2 
BVDME 1005 993 1055 883 1457 959 
 992 988 1044 889 1303 131
3 
 1018 861 934 743 - 973 
Mean 1005 947 1011 838 1380 108
2 
Standard deviation (sd) 13.0 74.8 66.9 82.6 108.9 200.
5 
 
9.1.2 Positive control values TA102 
 
Mutagen Positive 1 Positive 2 Positive 3 Mean sd 
TNFone Test 
1 
1306 1402 1375 1361 49.5 
TNFone Test 
2 
1051 1091 1081 1074 20.8 
AFB1 + S9  1115 1006 1003 1041 63.8 
t-BuOOH + 
S9 TEST 1  
1095 1112 1115 1107 10.8 
t-BuOOH + 
S9 TEST 2 
1251 - 1450 1351 140.7 
t-BuOOH – 
S9 
TEST 1 
1238 1050 1235 1174 107.7 
t-BuOOH – 
S9 
TEST 2 
1487 1311 1235 1344 129.3 
 
9.1. 3 Negative control values TA102 
 
Mutagen Neg 1 Neg 2 Neg 3 Neg 4  Neg 5  Neg 6 Mean sd 
TNFone 
Test 1  
371 318 235 369 320 399 335 58.4 
TNFone  276 234 268 268 255 291 265 19.4 
9. APPENDIX 87 
Test 2 
AFB1  
Test 
421 495 415 433 461 445 445 29.6 
t-BuOOH 
+ S9 
TEST 1 
444 308 431 412 411 391 400 48.4 
t-BuOOH 
+S9 
TEST 2 
418 509 517 511 450 515 487 42.1 
t-BuOOH  
-S9 
TEST 1 
388 333 348 346 331 355 350 20.7 
t-BuOOH  
- S9 
TEST 2 
434 439 383 486 505 396 441 48.1 
 
9.2.4 No treatment values TA102 
 
Mutagen No. of 
revertants 
No. of 
revertants 
No. of 
revertants 
Mean sd 
TNFone 1106 1121 1109 1112 7.9 
t-BuOOH + 
S9 
1902 1914 2003 1940 55.2 
t-BuOOH – 
S9 
1641 1653 - 1647 8.5 
AFB1 + S9 725 701 814 747 59.5 
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